Supporting Information for

Enzyme-Sialylation-Controlled Chemical Sulfation of Glycan Epitopes for Decoding the Binding of Siglec Ligands

Shengzhou Ma^{1,2,3†}, Pengfei Zhang^{1,2†}, Jinfeng Ye^{4†}, Yinping Tian^{1,2}, Xiao Tian⁵, Jaesoo Jung⁶, Matthew S Macauley^{6,7}, Jiabin Zhang^{1,3,5*}, Peng Wu^{4*}, Liuqing Wen^{1,2,3*}

¹Carbohydrate-Based Drug Research Center, ²State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

³University of Chinese Academy of Sciences, Beijing, 100049, China.

⁴Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, 92037, USA.

⁵Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong, 528400, China.

⁶Department of Chemistry, ⁷Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.

[†]These authors contributed equally to this work

*Corresponding Author: Email: jiabinzhang@simm.ac.cn (Jiabin Zhang); Email: pengwu@scripps.edu (Peng Wu); Email: lwen@simm.ac.cn (Liuqing Wen).

Table of	Contents
----------	----------

1	. Figures	3
	Figure S1	3
	Figure S2	4
	Figure S3	5
	Figure S4.	5
	Figure S5	9
2	. Materials and methods	10
3	. Experimental procedures	12
4	. Microarray Studies	68
	4.1 General procedure for Hydrogenolysis Mediated reduction of glycan terminal azide group	68
	4.2 Glycan microarray printing	68
	4.3 Screening of proteins	68
	4.4 MIRAGE compliant Glycan Microarray Document	69
5	. References	71
6	. NMR spectra	72

1. Figures



Figure S1 Structure determination of **67** (left) and **68** (right) via HSQC. H-8, H-9a, and H-9b signals of Neu5Ac were marked by a green rectangle on the left picture. A significant downfield shift corresponding to protons of -CH₂OH as new signals occurred at 4.45 ppm and 4.35 ppm compared with compound **67** revealed that the 6-OH of GlcNAc residue of compound **78** was sulfated. The HRMS data of both compounds were collected. For **67**: ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{46}N_5O_{22}S$, [M-H]⁻: 836.2361, found 836.2358. For **78**: ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{46}N_5O_{25}S_2$, [M-H]⁻: 916.1929, found 916.1925.



Figure S2 Structure determination of **85** via HSQC. The chemical shift of H-3' was a downfield move to 4.4 ppm, illustrating that electron-withdrawing group $-SO_3H$ occurred on the 3'-OH position of Gal residue of **85**. The sulfation of the 3'-OH of Gal has also affected the chemical shift of neighboring H-4' to the downfield shift.



Figure S3 The attempt to synthesize 97 and 98 from 11 and 13 using FucTs is unsuccessful as the FucTs cannot accept 11 or 13 as substrate.



Figure S4 Glycan microarray binding profiles of plant lectins (MAL I, SNA, ECL, PNA, and AAL). Appropriate protein concentrations were applied to screen the microarray. Histogram charts showing fluorescence intensities of binding of 5 plant lectins. Error bars represent the SD of the four values. *The highest relative fluorescence unit of the ligand is defined as 100%.







Figure S5 The histogram charts of the binding of Siglecs in humans. 50 µg/mL protein (Commercial source) concentrations were applied to screen the microarray. Lab-expressed Siglec-1 and -11 were used for screening after diluting ten folds (10X dilution) and one fold (1X dilution) individually. Siglec -1, -2, -3, -4, -7, -8, -9 -10, and -11 presented strong binding affinities with corresponding glycan ligands. Silgec -5, -6, and -15 displayed weak binding with glycans in the library. Error bars represent the SD of the four values. *The highest relative fluorescence unit of the ligand is defined as 100%. These histogram chart results corresponded to the main text's heat map of Fig. 8.

2. Materials and methods

Chemicals and solvents were purchased from Sigma-Aldrich unless otherwise stated and directly used without further purification. Chemical reactions were performed according to standard protocols, and enzymatic reactions were performed in aqueous buffers at an appropriate pH for each enzyme. Thin-layer chromatography (TLC) was performed on silica gel 60 F254 plates (Merck, MA) using p-anisaldehyde sugar stain and orcinol stain. Unless otherwise noted, all nuclear magnetic resonance (NMR) spectra were acquired on Bruker NMR spectrometer (500 MHz, 600 MHz, or 800 MHz) operating at 25 °C. Samples were dissolved in 99.96% D₂O, and chemical shifts were referenced to residual HDO signal at 4.79 ppm. Compounds **78**, **80**, **82** and **84** were dissolved in 99.8% CD₃OD to perform the same analysis. Data were obtained using LC-MS (Thermo HPLC-Orbitrap Elite). Ion-exchange chromatography was performed using a glass column (2.5 cm \times 20 cm) packed with anion-exchange resin (Cytiva). Size exclusion chromatography was performed using a glass column (2.5 cm \times 80 cm) packed with Bio-Gel P-2 fine resins (Bio-Rad, CA).

NHS-activated glass slides were purchased from Schott Inc. The printer and scanner for the glycan microarray were provided by Shanghai Wayen Biotech. Sugar nucleotides used in this work were prepared as reported previously.¹⁻³ Biotinylated plant lectins *Maackia amurensis* Lectin I (MAL I), *Sambucus nigra* Lectin (SNA), *Erythrina cristagalli* Lectin (ECL), *Peanut* agglutinin (PNA), and Aleuria Aurantia Lectin (AAL) were purchased from Vector Labs. Human Siglec -2, -3, -4, -5, -6, -7, -8, -9, -10 and -15 proteins (Fc-tag) were purchased from Acro Biosystems. Human Siglic-1, and -11 containing Fc-tag were designed as reported previously ⁴ and expressed using the HEK293 expression system in our lab. Biotinylated goat anti-Human IgG Fc Antibody and Streptavidin-AlexaFluor[®] 647 conjugate were purchased from Thermo Fisher Scientific.

CMP-Sialic acid synthetase from *Neisseria meningitides* (NmCSS),⁵ α 2,6-sialyltransferase from *Photobacterium damsela* (Pd2,6ST),⁶ Mutant α 2,6-sialyltransferase from *Photobacterium damsela* (M2,6ST),⁷ α 2,3-sialyltransferase from *Bibersteinia trehalosi* (BtST),⁸ α 2,3-sialyltransferase from *Photobacterium phosphoreum* (PPST),⁹ α 2,3/8-sialyltransferase from *Campylobacter jejuni* (CST II),¹⁰ sialidase from *Streptococcus penumoniae*¹¹ and α 1,3/4-fucosyltransferases from *Helicobacter pylori* (NCTC 11369 and UA948),¹² were prepared as reported previously.¹³⁻¹⁶ In detail, *E. coli* BL21 (DE3) cells harboring recombinant vector pET-28a were cultured in two liters of Luria–Bertani (LB) medium containing 50 µg/ml kanamycin in a rotary shaker at 37°C, 200 rpm. 0.2 mM of IPTG was added until OD was 0.8, and then protein expression was allowed to proceed at 16 °C overnight. The cells were harvested by centrifugation at 7000 rpm for 10 min. The cell precipitation was re-suspended in lysis buffer (50 mM Tris-HCl buffer, 300 mM NaCl, 10 mM imidazole; pH 7.5). Cells were disrupted by a microfluidizer and

the lysate was centrifuged at 12,000 g for 10 minutes to remove the cell debris. The His-tagged proteins were purified by using a Ni-NTA agarose column. Before purification, the column was equilibrated with the lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole; pH 7.5). The column was washed with 2 column volumes of the lysis buffer and eluted with elution buffer (50 mM Tris-HCl, 300 mM NaCl, 300 mM imidazole; pH 7.5). Protein concentration was determined by the BCA Protein Assay Kit.

3. Experimental procedures

General procedure for the installation of $\alpha 2$, 6-Neu5Ac using One-pot multi-enzymes (OPMEs) strategies. Acceptor (1.0 eq), Neu5Ac (1.5 eq), and CTP (2 eq) were dissolved at a final acceptor concentration of 20 mM in a tris-HCl buffer (100 mM, pH 8.5) containing 20 mM MgCl₂. Appropriate amounts of NmCSS and sialyltransferase (Pd2,6ST or M2,6ST) were successively added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, *v/v*). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing the product were collected and concentrated to give products. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing products were collected and loaded into the P-2 column again to remove the sodium chloride to afford products.

General procedure for the installation of $\alpha 2$, 6-9-N₃-Neu5Ac using One-pot multi-enzymes (OPMEs) strategies. Acceptor (1.0 eq), 9-N₃-Neu5Ac⁴⁴ (1.5 eq) and CTP (2 eq), were dissolved at a final acceptor concentration of 20 mM in a tris-HCl buffer (100 mM, pH 8.5) containing 20 mM MgCl₂. Appropriate amounts of NmCSS and sialyltransferase (Pd2,6ST or M2,6ST) were successively added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, *v/v*). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing products were collected and concentrated to give products. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product were collected and loaded into the P-2 column to remove the sodium chloride to afford the product.

General procedure for the sulfation of substrates and hydrolyzation of a2, 6-9-N₃-Neu5Ac by NanA. Substrate (1 eq) was dissolved in a mixed solution of DMF and TEA (9:1, *V: V*). SO₃/Py (8 eq) was then added under the ice bath. The reaction was stirred for 15 min at 0 °C and then continued to stir at r.t. for 1-2 h to achieve complete conversion. Monitoring reaction by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, v/v). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction after complete conversion. After purification by size-exclusion and ion-exchange column, the sulfated product was directly concentrated and dissolved at a final concentration of 10 mM in NaOAc buffer (50 mM, pH = 6.5), to solution add NanA (0.1 mg/mmol substrate) and incubated overnight at 37°C. Monitoring reaction by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, v/v). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product were collected and loaded into the P-2 column again to remove the sodium chloride to afford the product.

General procedure for the installation of TBDMS groups and hydrolyzation of 9-TBS-O-Neu5Ac by NanA. Substrate (1 eq) was dissolved in pyridine, and TBDMSCl (10 eq) was added to the above solution with an ice bath. The reaction was stirred for 15 min at 0°C and then continued to stir at r.t. for 1-2 h to drive it to completion. TLC (EtOAc/MeOH/H₂O, 10:3:2, ν/ν) monitors reaction. After the reaction finished, Et₃N was dropped into the reaction, and methanol was added to quench the reaction. The resulting solution was concentrated and diluted with water, washed with diethyl ether (×2), and the aqueous phase was concentrated to yield a crude product. The crudes were subsequently dissolved at a final concentration of 10 mM in NaOAc buffer (50 mM, pH = 6.5), added NanA (0.1 mg/mmol substrate), and incubated overnight at 37°C. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, ν/ν). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. Resulted solution was centrifuged, and the supernatant was concentrated and purified by reverse phase (C18) column chromatography (Phase A: 10 mM ammonium bicarbonate aqueous buffer; Phase B: Acetonitrile. 50%-70% of phase B gradient elution) to afford the product.

General procedure for the sulfation of substrates and removal of TBDMS group. Substrate (1 eq) was dissolved in a mixed solution of DMF and TEA (1:1, V: V). SO₃/Py (4 eq) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then continued to stir at 40 °C for 3-4 h to achieve complete conversion. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction after complete conversion. Subsequently, the mixed solution was directly concentrated and dissolved in water with 10 mg/mL of final concentration. The pH was adjusted to 3.0 using 1 M AcOH aqueous, and the resulting solution was stirred for 30 min at r.t. to perform the deprotection of the TBDMS group. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Once the reaction was finished, the pH of the mixture solution was neutralized utilizing 1 M NaOH aqueous to 7, and then the final solution was concentrated and purified by size-exclusion (P-2 gel) column utilizing DI water as eluent. The fractions containing products were collected and concentrated to give products. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product were collected and loaded into the P-2 column again to remove the sodium chloride to afford the sulfated product. Note: The detailed synthetic protocols of compounds 6, 9, 12, 15, 20, and 22 were described in the individual glycan synthetic section to ensure the production of the fewest C-3 OH sulfated by-products.

General procedure for the installation of α2, 3-9-N₃-Neu5Ac using One-pot multi-enzymes (OPMEs)

strategies. Acceptor (1.0 eq), 9-N₃-Neu5Ac (1.5 eq), and CTP (2 eq) were dissolved at a final acceptor concentration of 20 mM in a tris-HCl buffer (100 mM, pH 8.5) containing 20 mM MgCl₂. Appropriate amounts of NmCSS and sialyltransferase (BtST or PPST) were successively added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, v/v). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing products were collected and concentrated to give products. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product were collected and loaded into the P-2 column to remove the sodium chloride to afford the product.

General procedure for the di-sulfation of substrates and hydrolyzation of $\alpha 2$, 3-9-N₃-Neu5Ac by NanA. Substrate (1 eq) was dissolved in a mixed solution of DMF and Py (1:1, *V*: *V*). SO₃/Py (15 eq) was then added under the ice bath. The reaction was stirred for 1h at 0 °C to achieve complete conversion. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction after complete conversion. Subsequently, the mixed solution was directly concentrated and dissolved at a final concentration of 10 mM in NaOAc buffer (50 mM, pH = 6.5), to solution add NanA (0.1 mg/mmol substrate) and incubated overnight at 37°C. Monitoring reaction by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, v/v). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing products were collected and concentrated to give products. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product were collected and loaded into the P-2 column to remove the sodium chloride to afford the product.

General procedure for the synthesis of fucosylated glycan backbones. Acceptor (1 eq) GDP-Fuc (1.5 eq) were dissolved at a final acceptor concentration of 10 mM in a tris-HCl buffer (100 mM, pH 7.5) containing 10 mM MgCl₂. Appropriate amounts of FucT were added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing the product were collected and concentrated to give the product. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product. For the purification

of compounds **94** and **99** that containing the TBDMS group, The resulting solution was centrifuged and the supernatant was concentrated and purified by reverse phase (C18) column chromatography (Phase A: 10 mM ammonium bicarbonate aqueous buffer; Phase B: Acetonitrile. 50%-70% of phase B gradient elution) to afford the product. (**Notes:** Glycan **6**, **7**, **11**, **12**, and **13** were also performed using the fucosylated procedure, but the reactions failed.)

General procedure for the a2, 6-sialylation of sulfated glycan backbones. Acceptor (1 eq) and CMP-Neu5Ac (1.5 eq) were dissolved at a final acceptor concentration of 10 mM in a tris-HCl buffer (100 mM, pH 8.5) containing 5 mM MgCl₂. Appropriate amounts of sialyltransferase (Pd2,6ST) were added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, v/v). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing the product were collected and concentrated to give the product. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product.

General procedure for the $\alpha 2$, 3-sialylation of glycan backbones. Acceptor (1 eq) and CMP-Neu5Ac (1.5 eq) were dissolved at a final acceptor concentration of 10 mM in a tris-HCl buffer (100 mM, pH 8.5) containing 5 mM MgCl₂. Appropriate amounts of sialyltransferase (BtST or PPST) were added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, ν/ν). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The fractions containing the product were collected and concentrated to give the product. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product.

General procedure for the installation of $\alpha 2$, 8-Neu5Ac using CST II. Acceptor (1 eq) and CMP-Neu5Ac (1.5 eq) were dissolved at a final acceptor concentration of 10 mM in a tris-HCl buffer (100 mM, pH 8.5) containing 5 mM MgCl₂. Appropriate amounts of sialyltransferase (CST II) were added to the reaction solution. The reaction mixture was incubated at 37°C and monitored by TLC (EtOAc/MeOH/H₂O/HOAc, 4:2:1:0.2, ν/ν). Once the reaction finished, the reaction was quenched by adding an equal volume of cold ethanol. The solution was centrifuged, and the supernatant was concentrated and purified using a size-exclusion (P-2 gel) column utilizing DI water as an eluent. The

fractions containing the product were collected and concentrated to give the product. If needed, further purification was performed by ion-exchange column by gradient elution using sodium chloride solution (0-500 mM). The fractions containing the product were collected and loaded into the P-2 column to remove the sodium chloride to afford the product.



Synthesis of 23

23 was prepared from 1^{17} using sialyltransferase Pd2,6ST according to the general procedure in the methods and was the white solid after lyophilization (1.4 g, yield 88%). ESI-Q-TOF-HRMS m/z calculated for C₂₈H₄₈N₅O₁₉, [M-H]⁻: 758.2938, found 758.2935.

	,	- 2 -).	- (PP)					1	1		1	1		
	H1	H2	H3		H4		H5	<u> H6</u>		H7	H8	H9	NHAc	
GlcNAc	4.57 (d,	3.75	N/R		3.64		3.63	4.0	0,	-	-	-	2.08	(s,
	J = 8.3							3.8	4				3H)	or
	Hz, 1H)												2.04	(s,
													3H)	
Gal	4.45 (d,	3.55	N/R		3.93 (dd,	3.83	3.9	9,	-	-	-	-	
	J = 8.0				J = 3	3.4,		356	5					
	Hz, 1H)				1.0 H	Hz,								
	, ,				1H)	Í								
Neu5Ac	-	-	2.68 (d	d, $J =$	3.67		3.81	3.7	7	N/R	3.89	3.88,	2.08	(s,
			12.4, 4	.7 Hz,								3.65	3H)	or
			1H), 1.7	72 (t, J									2.04	(s,
			= 12.2 H	Iz, 1H)									3H)	
¹³ C NMR ((151 MHz	, D ₂ O):	δ (ppm)											
	C1	C2	C3	C4	C5	C6		C7	C8	(C 9	NHAc		
GlcNAc	100.93	54.86	N/R	80.73	74.45	60.	35 -	-	-	-		22.26 or	22.01	

¹H NMR (600 MHz, D₂O): δ (ppm)

GlcNAc	100.93	54.86	N/R	80.73	74.45	60.35	-	-	-	22.26 or 22
Gal	103.47	70.72	N/R	N/R	73.67	63.32	-	-	-	-
Neu5Ac	173.51	100.14	40.07	N/R	51.87	N/R	N/R	71.69	62.63	22.26 or 22

Linker	1	2	3
Н	3.44 – 3.35 (m, 2H)	1.89 – 1.81 (m, 2H)	3.99, 370
С	47.77	28.10	67.10

N/R: not reported.



.01

Synthesis of 24

24 was prepared from 2^{18} using sialyltransferase Pd2,6ST according to the general procedure in the methods and was the white solid after lyophilization (790 mg, yield 94%). ESI-Q-TOF-HRMS m/z

calculated for $C_{26}H_{43}N_4O_{19}$, [M-H]⁻: 715.2527, found 715.253.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.50	3.35 (t,	3.67	3.63	3.62	3.98,	-	-	-	-
	(d, J =	J = 8.6				3.81				
	8.1	Hz,								
	Hz,	1H)								
	1H)									
Gal	4.44	3.57 -	3.66	3.95	3.82	3.98,	-	-	-	-
	(d, J =	3.51		(d, J =		3.61				
	7.9	(m,		3.4						
	Hz,	1H)		Hz,						
	1H)			1H)						
Neu5Ac	-	-	2.72 (dd, J	3.66	3.87	3.73	3.57	3.89	3.89,	2.04 (s,
			= 12.3, 4.7			(dd, J =	(dd, J =		3.65	3H)
			Hz, 1H),			10.5, 1.7	9.3, 1.8			
			1.75 (t, $J =$			Hz, 1H)	Hz,			
			12.2 Hz,				1H)			
			1H)							

¹H NMR (600 MHz, D₂O): δ (ppm)

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
Glc	101.91	72.63	74.52	79.52	74.55	60.16				
Gal	103.11	70.69	72.43	68.28	73.60	63.47				
Neu5Ac	17339	100.20	40.01	68.28	51.69	72.27	68.42	71.70	62.54	21.96

Linker	1	2	3
Н	3.48 (t, J = 6.7 Hz, 2H)	1.97 – 1.89 (m, 2H)	4.01, 3.78
С	47.79	28.14	67.24



Synthesis of 25

25 was synthesized from 3^{19} using sialyltransferase Pd2,6ST according to the general procedure in the methods and white solid after lyophilization (985 mg, yield 92%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{46}N_5O_{19}$, [M-H]⁻: 756.2792, found 756.2795.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.57 (d, J	3.84	3.75	3.54	3.53	4.00,	-	-	-	2.03 (s,
	= 8.4 Hz,					3.80				6H)
	1H)									
Gal	4.38 (d, J	3.53	3.65	3.93	3.73	3.98,	-	-	-	-
	= 7.8 Hz,					3.59				
	1H)									
Neu5Ac	-	-	2.70 (dd, $J = 12.4$,	3.66	3.83	3.81	3.58	3.89	3.89,	2.03 (s,
			4.6 Hz, 1H), 1.71						3.65	6H)
			(t, J = 12.2 Hz, 1H)							

¹H NMR (500 MHz, D₂O): δ (ppm)

¹³C NMR (126 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	С9	NHAc
GlcNAc	100.91	54.32	84.06	68.42	75.48	60.89	-	-	-	22.21 or 22.06
Gal	103.94	70.52	72.40	68.25	72.47	63.52	-	-	-	-
Neu5Ac	173.37	100.05	40.09	68.45	51.80	73.59	68.92	71.77	62.65	22.21 or 22.06

Linker	1	2	3
Н	3.38 (td, J = 6.6, 1.6 Hz, 2H)	1.90 – 1.81 (m, 2H)	4.00, 3.71
С	47.80	28.10	67.16



26 was synthesized from **4**¹⁹ using sialyltransferase M2,6ST according to the general procedure in the methods and white solid after lyophilization (474 mg, 97%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{46}N_5O_{19}$, [M-H]⁻: 756.2792, found 756.2792.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.51 (d, J	4.02	3.89	4.20	3.73	3.82	-	-	-	2.04
	= 8.5 Hz,									
	1H)									
Gal	4.44 (d, J	3.53	3.62	3.92	3.77	3.91,	-	-	-	-
	= 7.8 Hz,					3.65				
	1H)									
Neu5Ac	-	-	2.75 (dd, $J = 12.4$,	3.69	3.83	3.72	3.60	3.89	3.90,	2.04
			4.5 Hz), 1.69 (t, $J =$						3.65	
			12.2 Hz)							
¹³ C NMR (201 MHz, D	₂ Ο): δ	(ppm)							

¹H NMR (600 MHz, D₂O): δ (ppm)

	201 10111	$2, \boldsymbol{\nu}_2 \circ \boldsymbol{j}$	(ppm)							
	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GalNAc	101.41	51.22	79.93	67.96	74.85	61.14	-	-	-	22.22
Gal	104.71	70.46	72.58	68.22	73.15	63.39	-	-	-	-
Neu5Ac	173.41	100.41	40.16	68.47	51.84	72.34	68.17	71.74	62.60	22.00

Linker	1	2	3
Н	3.39	1.86	4.00, 3.70
С	47.78	28.10	67.00



Synthesis of 69

1 was treated following the general procedure in the methods to install 9-N₃-Neu5Ac giving **69** as the white solid after lyophilization (1.3 g, yield 81%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{45}N_8O_{18}$, [M-H]⁻: 781.2857, found 781.2859.

	H1	H2	H3			H4	H5	H6	H	[7	H8	H9	NHA	c
GlcNAc	4.54 (d, J	3.72	3.74			3.61	3.59	3.97	-		-	-	2.05	or
	= 7.8 Hz,							3.81					2.01	
	1H)													
Gal	4.43 (d, J	3.52	3.72			3.91	3.82	3.97	-		-	-	-	
	= 7.9 Hz,							3.52						
	1H)													
Neu5Ac	-	-	2.64 (dd, $J =$	12.4,	3.63	3.79	3.72	3	.54	4.01	3.65,	2.05	or
			4.7 H	z, 1H),	1.69							3.48	2.01	
			(t, J =	12.2 Hz	, 1H)									
¹³ C NMR ((151 MHz,	D ₂ O): &	6 (ppm)											
	C1 C	22	C3	C4	C5	C6	C	7	C 8	C	9	NHAc		

¹H NMR (600 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	100.91	54.85	72.34	80.73	74.44	60.32	-	-	-	22.26 or 22.01
Gal	103.47	70.68	72.38	68.32	73.66	63.32	-	-	-	-
Neu5Ac	173.51	100.16	40.08	68.17	51.85	72.38	69.00	70.23	53.09	22.26 or 22.01

Linker	1	2	3
Н	3.36	1.83	3.96, 3.66
С	47.75	28.09	67.08



Synthesis of 71

2 was treated following the general procedure in the methods to install 9-N₃-Neu5Ac giving **71** as the white solid after lyophilization (320 mg, yield 92%). ESI-Q-TOF-HRMS m/z calculated for $C_{26}H_{44}N_7O_{18}$, $[M+H]^+$: 742.2737, found 742.2742.

¹H NMR (600 MHz, D₂O): δ (ppm)

Ì	H1	H2	H3	H4	H5		H6	H7	H8	H9	NHAc
Glc	4.48 (d,	3.33 (t,	3.65	3.60	3.58		3.96,	-	-	-	-
	J = 8.0	J = 8.5					3.79				
	Hz, 1H)	Hz, 1H)									
Gal	4.41 (d,	3.52	3.64	3.92	3.79		3.95,	-	-	-	-
	J = 7.9						3.58				
	Hz, 1H)										
Neu5Ac	-	-	2.69 (dd, J	= 3.64	3.84	(t,	3.74	3.55	4.01	1 3.68,	2.02 (s,
			12.4, 4.7 H	z,	J = 1	10.1				3.49	3H)
			1H), 1.72 (t,	J	Hz,	1H)					
			= 12.2 Hz, 1H	D		-					
¹³ C NMR ((151 MHz	$, D_2O): \delta($	ppm)								
	C1	C2 (C3 C4	C5	C6	C7	C8	C 9)	NHAc	

Glc	101.96	72.67	74.56	79.57	74.60	60.20	-	-	-	-
Gal	103.15	70.72	72.67	68.45	73.66	63.55	-	-	-	-
Neu5Ac	173.45	100.29	40.07	68.31	51.73	72.28	68.97	70.30	53.06	22.02

Linker	1	2	3
Н	3.45 (t, J = 6.7 Hz, 2H)	1.90 (p, J = 6.7 Hz, 2H)	3.98, 3.75
С	47.82	28.19	67.28



3 was treated following the general procedure in the methods to install 9-N₃-Neu5Ac giving **73** as the white solid after lyophilization (738 mg, yield 88%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{45}N_8O_{18}$, [M-H]⁻: 781.2857, found 781.2858.

¹ H NMR	(600 MHz,	D_2O): δ	(ppm)
--------------------	-----------	--------	------	-------

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.55 (d,	3.80	3.73	3.50	3.49	3.97,	-	-	-	2.06 -
	J = 8.5					3.77				1.97 (m,
	Hz, 1H)									6H)
Gal	4.36 (d,	3.50	3.62	3.89 (d,	3.79	3.95,	-	-	-	-
	J = 7.8			J = 3.5		3.54				
	Hz, 1H)			Hz, 1H)						
Neu5Ac	-	-	2.68 (dd, $J =$	3.64	3.81	3.74	3.55	4.01	3.65,	2.06 –
			12.4, 4.7 Hz,						3.48	1.97 (m,
			1H), 1.67 (t, $J =$							6H)
			12.2 Hz, 1H)							-
¹³ C NMR ((151 MHz,	D ₂ O):	δ (ppm)							

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	103.88	54.26	84.02	69.02	75.43	60.83	-	-	-	22.17 or 22.03
Gal	100.86	70.45	72.21	68.40	73.57	63.48	-	-	-	-
Neu5Ac	173.45	100.09	40.12	68.22	51.76	72.34	68.87	70.29	53.07	22.17 or 22.03

Linker	1	2	3
Н	3.40 – 3.34 (m, 2H)	1.83 (p, J = 6.4 Hz, 2H)	3.97, 3.67
С	47.75	28.05	67.11



Synthesis of 75

4 was treated following the general procedure in the methods to install 9-N₃-Neu5Ac giving 75 as the white solid after lyophilization (307 mg, 91%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{45}N_8O_{18}$, [M-

H]⁻: 781.2857, found 781.2854.

	$500 \text{ MHZ}, D_2$	(0).0(ppin)	-	-		-	-	-	-
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.50 (d, J	4.01	3.88	4.19	3.72	3.82	-	-	-	2.05,
	= 8.6 Hz,									2.04
	1H)									
Gal	4.44 (d, J	3.52	3.62	3.93	3.72	3.91,	-	-	-	-
	= 7.8 Hz,					3.65				
	1H)									
Neu5Ac	-	-	2.73 (dd, $J = 12.4$,	3.68	3.82	3.72	3.60	4.01	3.69,	2.05,
			4.7 Hz), 1.65 (t, $J =$						3.50	2.04
			12.1 Hz)							

¹H NMR (600 MHz, D₂O): δ (ppm)

¹³C NMR (201 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GalNAc	101.41	51.23	79.91	67.96	74.86	61.15	-	-	-	22.21
Gal	104.67	70.44	72.38	68.21	73.13	63.37	-	-	-	-
Neu5Ac	173.39	100.42	40.17	68.45	51.83	72.34	68.83	70.30	53.06	22.00

Linker	1	2	3
Н	3.40	1.86	3.99, 3.69
С	47.78	28.09	66.99



Synthesis of 5

69 was treated via the general procedure in the methods to provide 5 as the white solid after lyophilization

(104 mg, yield 74% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{31}N_4O_{14}S$, $[M+H]^+$: 547.1552, found 547.1552.

¹ H NMR	(800 MHz,	D ₂ O):	δ	(ppm))
--------------------	-----------	--------------------	---	-------	---

(, , ,											
	H1	H2				H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.54	3.73				3.70	3.77	3.79	4.38,	-	-	-	2.03
									4.32				
Gal	4.52	3.52 (dd,	J = 10	.0, 7.9	Hz,	3.67	3.92	3.71	3.74	-	-	-	-
		1H)											
¹³ C NMR ((201 M	Hz, D ₂ O):	δ (ppm))									
	C1	C2	C3	C4	C5	C	6 (~7 C	8 C9	NHAc			

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	101.15	55.06	72.26	77.36	72.50	66.25	-	-	-	22.14
Gal	102.49	70.96	72.45	68.58	75.32	61.02	-	-	-	-

Linker	1	2	3
Н	3.36	1.83	3.95, 3.68
С	47.76	28.07	67.26



71 was treated via the general procedure in the methods to provide **8** as the white solid after lyophilization (47 mg, yield 71% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{15}H_{26}N_3O_{14}S$, [M-H]⁻: 504.1141, found 504.1144.

¹H NMR (500 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.52	$3.34 (\mathrm{dd}, J =$	3.65	3.74	3.82	4.40 (dd, $J = 11.1$, 2.1	-	-	-	-
		9.4, 8.0 Hz,				Hz, 1H), 4.31 (dd, $J =$				
		1H)				11.1, 4.2 Hz, 1H)				
Gal	4.52	$3.54 (\mathrm{dd}, J =$	3.68	3.93 (d, J	3.74	3.78 (2H)	-	-	-	-
		9.9, 7.9 Hz,		= 3.4 Hz,						
		1H)		1H)						

¹³C NMR (126 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
Glc	102.07	72.56	75.18	77.05	72.37	66.09	-	-	-	-
Gal	102.37	70.82	72.33	68.46	74.08	60.88	-	-	-	-

Linker	1	2	3
Н	3.49 – 3.43 (m, 2H)	1.96 – 1.88 (m, 2H)	4.04 – 3.96 (m, 1H), 3.78
С	47.72	28.10	67.38



Synthesis of 11

73 was treated via the general procedure in the methods to provide **11** as the white solid after lyophilization (41 mg, yield 59% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{29}N_4O_{14}S$, [M-H]⁻: 545.1406, found 545.1406.

'H NMK (800 MHZ, D ₂ O): 0 (p	(ppm)
------------------------------------------	-------

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.58 (d,	3.87 –	3.81	3.60 (dd,	3.72	4.38 (dd, J =	-	-	-	2.05 (s,
	J = 8.3	3.84 (m,		J = 10.0,		11.3, 2.1 Hz,				3H)
	Hz,	1H)		8.5 Hz,		1H), 4.24 (dd,				
	1H)			1H)		J = 11.2, 5.6				
						Hz, 1H)				
Gal	4.45 (d,	3.53 (dd,	3.65	3.92 (d, J	3.71	3.79, 3.75	-	-	-	-
	J = 7.8	J = 10.0,	(dd, J =	= 3.4 Hz,						
	Hz,	7.8 Hz,	9.9, 3.4	1H)						
	1H)	1H)	Hz, 1H)							

¹³C NMR (201 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	103.49	54.55	81.99	68.43	73.26	67.10	-	-	-	22.21
Gal	100.960	70.66	72.48	68.55	75.27	61.01	-	-	-	-

Linker	1	2	3
Η	3.42 – 3.36 (m, 2H)	1.90 – 1.81 (m, 2H)	3.99 (dt, J = 10.9, 5.6 Hz, 1H), 3.70
С	47.79	28.10	67.30



75 was treated via the general procedure in the methods to provide **14** as the white solid after lyophilization (62 mg, 68% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{29}N_4O_{14}S$, [M-H]⁻: 545.1406, found 545.1409.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.54 (d, $J = 8.5$	4.04	3.92	4.26	3.97	3.22	-	-	-	2.05
	Hz, 1H)									
Gal	4.46 (d, $J = 7.8$	3.55 (dd, J = 10.1,	3.64	3.93	3.69	3.77	-	-	-	-
	Hz, 1H)	7.6 Hz, 1H)								
120100		()								

¹³C NMR (201 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GalNAc	101.35	51.16	79.70	67.71	72.37	67.19	-	-	-	22.19
Gal	104.85	70.57	72.47	68.57	74.94	60.94	-	-	-	-

Linker	1	2	3
Н	3.40	1.87	3.98, 3.73
С	47.80	28.12	67.19



Synthesis of 78

23 was treated via the general procedure in the methods to provide **78** as the white solid after lyophilization (280 mg, yield 73% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{43}N_4O_{11}Si$, [M-H]^{-:} 579.2703, found 579.2705.

¹H NMR (600 MHz, CD₃OD): δ (ppm)

Č.	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.39 (d,	3.72	3.65 –	3.70	3.39	4.04 (dd, J =	-	-	-	1.99 (s,
	J = 8.4		3.61 (m,			11.6, 3.9 Hz,				3H)
	Hz, 1H)		1H)			1H), $3.99 (dd, J =$				
						11.6, 1.8 Hz, 1H)				

Gal	4.44 (d	, 3.53	3.45	(dd, 3.	82 (dd,	3.52	3.77	, 3.67	7	-	-	-	-
	J = 7.7	7	J =	9.7, <i>J</i>	= 3.3,								
	Hz, 1H)		3.3	Hz, 1.	0 Hz,								
			1H)	1H	H)								
¹³ C NMR ((151 MHz	z, CD ₃ O	D): δ (p	pm)									
	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc			
GlcNAc	101.35	55.31	72.74	77.90	75.40	61.50	-	-	-	21.61			
Gal	103,26	71.23	73.56	68.99	75.92	61.23	-	-	-	-			

Linker	1	2	3
Η	3.39 (2H)	1.87 – 1.75 (m, 2H)	3.92 (ddd, J = 9.9, 6.1, 5.1 Hz, 1H), 3.59 - 3.56 (m, 1H)
С	47.36	28.79	65.66

TBS Group	1'	2'	3'
Η	0.94 (s, 9H)	-	0.13 (d, J = 8.4 Hz, 6H)
С	25.11	17.85	-6.15, -6.43



24 was treated via the general procedure in the methods to provide **80** as the white solid after lyophilization (507 mg, yield 80% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{21}H_{41}N_3NaO_{11}Si$, [M+Na]⁺: 562.2403, found 562.2403.

¹H NMR (600 MHz, CD₃OD): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.26 (d, J	3.23 (dd, J	3.51	3.64	3.39 –	4.03 - 3.95	-	-	-	-
	= 7.8 Hz,	= 9.3, 7.8			3.36 (m,	(m, 2H)				
	1H)	Hz, 1H)			1H)					
Gal	4.40 (d, J	3.52	3.44	3.81 (dd, J	3.51	3.80 - 3.75	-	-	-	-
	= 7.7 Hz,			= 3.4, 1.0		(m, 1H), 3.70				
	1H)			Hz, 1H)		– 3.66 (m, 1H)				

¹³C NMR (151 MHz, CD₃OD): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
Glc	104.19	74.89	76.31	78.97	76.65	62.88	I	-	I	-
Gal	104.64	72.57	74.78	70.30	77.17	62.53	-	-	-	-

Linker	1	2	3
Н	3.44 (2H)	1.91 – 1.84 (m, 2H)	3.95 – 3.90 (m, 1H), 3.64
С	49.43	30.29	67.53

TBS group	1'	2'	3'
Η	0.92 (s, 9H)	-	0.11 (s, 3H), 0.10 (s, 3H)
С	26.47	19.22	-4.79, -5.07



25 was treated via the general procedure in the methods to provide **82** as the white solid after lyophilization (186 mg, yield 61% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{43}N_4O_{11}Si$, [M-H]⁻: 579.2703, found 579.2702.

¹H NMR (600 MHz, CD₃OD): δ (ppm)

	· · · · · · · · · · · · · · · · · · ·	<u> </u>	<u>/···(FI</u>												
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc					
GlcNAc	4.46 (d, J	3.73	3.69	3.47	3.31	$3.99 (\mathrm{dd}, J = 11.3,$	-	-	-	1.99 (s,					
	= 8.3 Hz,					1.9 Hz, 1H), 3.85				3H)					
	1H)					(dd, J = 11.4, 5.1)				,					
						Hz, 1H)									
Gal	4.29 (d, J	3.55	3.47	3.82 (dd, J	3.57	3.77, 3.71	-	-	-	-					
	= 7.6 Hz,			= 3.4, 1.0											
	1H)			Hz, 1H)											
13C NMR	(151 MHz)		$) \cdot \delta (n$	nm)					•						

e i unit		$\underline{L}, \underline{C}\underline{L}, \underline{C}\underline{C}$	<u> </u>	(pm)						
	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHA
GlcNAc	102.43	56.28	84.89	70.25	77.75	63.90	-	-	-	23.21
Gal	105.62	72.39	74.68	70.18	77.14	62.53	-	-	-	-

Linker	1	2	3
Η	3.42 – 3.37 (m, 2H)	1.88 – 1.77 (m, 2H)	3.96 – 3.90 (m, 1H), 3.59
C	48.89	30.16	67.24

TBS group	1′	2'	3'
Η	0.93 (s, 9H)	-	0.11 (s, 3H), 0.11 (s, 3H)
С	26.44	19.32	-4.98, -5.09



Synthesis of 84

26 was treated via the general procedure in the methods to provide **84** as the white solid after lyophilization (88 mg, 79%). ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{43}N_4O_{11}Si$, [M-H]⁻: 579.2703, found 579.2702. ¹H NMR (600 MHz, CD₂OD)⁻ δ (ppm)

	minin (ooo mile, eb30b). o (ppin)											
	H1			H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.43 (d,	J = 8.5	Hz, 1H)	3.99	3.76	4.09	3.53	3.82	-	-	-	1.95
Gal	4.31 (d,	J = 7.6	Hz, 1H)	3.53	3.43	3.82	3.50	3.69	-	-	-	-
¹³ C NMR (¹³ C NMR (201 MHz, CD ₃ OD): δ (ppm)											
	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHA	Ac	

GalNAc	101.47	51.75	80.02	67.85	74.97	62.10	-	-	-	172.86, 21.82
Gal	105.26	71.11	73.18	68.60	75.11	60.86	-	-	-	-

Linker	1	2	3
Н	3.37	1.82	3.90, 3.56
С	47.83	28.76	65.69

TBS Group	1'	2'	3'
Η	0.9	-	0.09
С	24.98	17.77	-6.57, -6.63



78 was treated according to the general procedure in the methods to give **6** as the white solid after lyophilization (363 mg, yield 77% for 2 steps). In detail, **78** (500 mg, 0.86 mmol) was dissolved in a mixed solution of 3 mL DMF and 3 mL TEA. SO₃/Py (548 mg, 3.45 mmol) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then stirred at 40 °C for 4 h. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, *v/v*). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction. Subsequently, the reaction crude was treated according to the general procedure in the methods to deprotect the TBDMS group to give **6**. ESI-Q-TOF-HRMS m/z calculated for C₁₇H₂₉N₄O₁₄S, [M-H]^{-:} 545.1406, found 545.1405.

		, 2	-)	Tr /								
	H1	H2	H3	H4	H5	H6			H7	H8	H9	NHAc
GlcNAc	4.57	3.78	3.77	3.73	3.66	4.03, 3	3.88		-	-	-	2.09 (s, 3H)
Gal	4.55	3.58	3.73	4.03	4.01	4.28 -	4.22 (n	n, 2H)	-	-	-	-
¹³ C NMR	¹³ C NMR (126 MHz, D ₂ O): δ (ppm)											
	C1	C2	. (C 3	C4	C5	C6	C7	C8	C9	NHA	2
GlcNAc	101.1	0 55.	.16 7	2.15	79.17	74.69	60.24	-	-	-	22.20	
Gal	102.8	0 70.	.81 7	2.33	68.25	72.81	67.13	-	-	-	-	

¹ H NMR ((500 MHz,	D_2O):	(ppm)
----------------------	-----------	--------	----	-------

Linker	1	2	3
Н	3.47 – 3.37 (m, 2H)	1.94 – 1.83 (m, 2H)	4.00, 3.72
С	47.79	28.10	67.19



Synthesis of 9

80 was treated according to the general procedure in the methods to give **9** as the white solid after lyophilization (123 mg, yield 66% for 2 steps). In detail, **80** (200 mg, 0.37 mmol) was dissolved in a mixed

solution of 2 mL DMF and 2 mL TEA. SO₃/Py (236 mg, 1.48 mmol) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then stirred at 40 °C for 3 h. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction. Subsequently, the reaction crude was treated according to the general procedure in the methods to deprotect the TBDMS group to give 9. ESI-Q-TOF-HRMS m/z calculated for C₁₅H₂₆N₃O₁₄S, [M-H]⁻: 504.1141, found 504.1141.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	
Glc	4.48	3.37 – 3.31 (m, 1H)	3.66	3.62	3.62	4.00, 3.81	-	-	-	-	
Gal	4.48	$3.56 (\mathrm{dd}, J = 9.9, 7.9 \mathrm{Hz},$	3.69	3.98	3.99	4.24 - 4.18 (m,	-	-	-	-	
		1H)				2H)					
13C N	³ C NMP (126 MHz D O): § (nnm)										

¹ H NMR	(500 MHz,	D_2O): δ	(ppm))
--------------------	-----------	--------	------	-------	---

	CI	C2	C3	C4	05	C6	\mathbf{C}	Cð	C9	NHA
Glc	101.90	72.73	74.23	79.28	74.56	60.10	-	-	-	-
Gal	102.94	70.62	72.19	68.12	72.62	67.16	-	-	-	-

Linker	1	2	3
Н	3.49 – 3.43 (m, 2H)	1.96 – 1.87 (m, 2H)	4.01, 3.76
С	47.74	28.10	67.21



Synthesis of 12

82 was treated according to the general procedure in the methods to give 12 as the white solid after lyophilization (53 mg, yield 70% for 2 steps). In detail, 82 (80 mg, 0.14 mmol) was dissolved in a mixed solution of 0.5 mL DMF and 0.5 mL TEA. SO₃/Py (89 mg, 0.56 mmol) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then stirred at 40 °C for 3 h. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction. Subsequently, the reaction crude was treated according to the general procedure in the methods to deprotect the TBDMS group to give 12. ESI-Q-TOF-HRMS m/z calculated for C₁₇H₂₉N₄O₁₄S, [M-H]⁻: 545.1406, found 545.1404.

		$, D_2 O_{j}.$	o (ppin)											
	H1		H2		H3	H4	H5	H6		H7	H8	H9	NHA	c
GlcNAc	4.56 (d,	$J = \begin{bmatrix} 1 \\ 1 \end{bmatrix}$	3.84 (de	d, J =	3.78	3.51	3.49	3.92,	3.76	-	-	-	2.04	(s,
	8.4 Hz,	1H)	10.4, 8	.4 Hz,									3H)	
			1H)											
Gal	4.45 (d,	$J = \begin{bmatrix} 1 \\ 1 \end{bmatrix}$	3.53		3.65	3.96	3.96	4.26	- 4.1	5 -	-	-	-	
	7.8 Hz,	1H)						(m, 2	2H)					
¹³ C NMR ((126 MHz	z, D ₂ O)	: δ (ppm)										
	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc				
GlcNAc	103.59	54.45	82.89	68.26	75.30	60.66	5 -	-	-	22.18				

¹ H NMR	(500 MHz,	D ₂ O): δ	(ppm
--------------------	-----------	----------------------	------

Gal	100.91	70.48	72.26	68.73	72.77	67.37	-	-	-	-
-----	--------	-------	-------	-------	-------	-------	---	---	---	---

Linker	1	2	3
Н	3.44 – 3.32 (m, 2H)	1.90 – 1.80 (m, 2H)	3.99, 3.67
С	47.76	28.07	67.14

	84	2 steps	15	
он он но он он		1) SO ₃ /Py DMF, TEA 2) AcOH, pH=3.0 61%	OH-OSO3HHO OH HO OH OH NHA	.OR Ac

84 was treated according to the general procedure in the methods to give **15** as the white solid after lyophilization (20 mg, 61% for 2 steps). In detail, **84** (35 mg, 0.06 mmol) was dissolved in a mixed solution of 0.5 mL DMF and 0.5 mL TEA. SO₃/Py (38 mg, 0.24 mmol) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then stirred at 40 °C for 3 h. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, *v/v*). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction. Subsequently, the reaction crude was treated according to the general procedure in the methods to deprotect the TBDMS group to give **15**. ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{29}N_4O_{14}S$, [M-H]^{-:} 545.1406, found 545.1406.

1 H NMR ((500 MHz,	D_2O): δ	(ppm)
----------------	-----------	--------	------	-------

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.50 (d, $J = 8.5$	4.02	3.86	4.24	3.72	3.80	-	-	-	2.05
	Hz, 1H)									
Gal	4.46 (d, $J = 7.8$	$3.54 (\mathrm{dd}, J = 9.9, 7.9$	3.65	3.96	3.90	4.19	-	-	-	2.05
	Hz, 1H)	Hz, 1H)								
¹³ C NMR ($(126 \text{ MHz} \text{D}_2\text{O}) \cdot \delta$	(ppm)								

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GalNAc	101.38	51.15	80.04	68.03	74.92	61.18	-	-	-	22.19
Gal	104.66	70.42	72.32	68.32	72.52	67.47	-	-	-	-

Linker	1	2	3
Н	3.40	1.87	4.01, 3.70
С	47.78	28.09	66.99



Synthesis of 86

86 was synthesized using sialyltransferase BtST via the general procedure in the methods and white solid after lyophilization (289mg, 86%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{45}N_8O_{18}$, [M-H]⁻: 781.2857, found 781.2856.

¹ H NMR (600 MHz, D_2O): δ (ppm)								
	H1	H2	H3					

H4

H5

H6

H7

H8

H9

NHAc

GlcNAc	4.51	3.72	3.69				3.71	3.57	3.99,	-	-	-	2.03 or
									3.83				2.02
Gal	4.53	3.56	4.0)9			3.93	3.67	3.72	-	-	-	-
Neu5Ac			2.7	$2.74 (\mathrm{dd}, J = 12.4, 4.6 \mathrm{Hz},$				3.84	3.72	3.58	4.01	3.67,	2.03 or
			1H	1H), 1.76								3.48	2.02
¹³ C NMR (151 MHz, D ₂ O): δ (ppm)													
	C1	C2		C3	C4	C5	C6	C7	C8	C9	Ν	HAc	
GlcNAc	101.1	2 55.	.06	72.33	78.26	74.76	60.05	-	-	-	22	2.15	
Gal	102.5	5 69.	.37	75.51	67.39	75.14	61.00	-	-	-	-		
Neu5Ac	173.8	0 99.	78	39.67	68.32	51.65	72.67	68.72	2 70.35	53.04	22	2.15	

Linker	1	2	3
Н	3.36	1.83	3.98, 3.65
С	47.75	28.09	67.11



88 was synthesized using sialyltransferase BtST via the general procedure in the methods and white solid after lyophilization (460 mg, 88%). ESI-Q-TOF-HRMS m/z calculated for $C_{26}H_{42}N_7O_{18}$, [M-H]⁻: 740.2592, found 740.2592.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.50 (d,	3.33	3.65	3.67	3.61	4.02,	-	-	-	-
	J = 8.0	(dd, J =				3.83				
	Hz,	9.1, 7.9								
	1H)	Hz, 1H)								
Gal	4.53 (d,	3.58	4.11 (dd, J =	3.96 (d,	3.71	3.75	-	-	-	-
	J = 7.9		9.9, 3.2 Hz,	J = 3.2		(2H)				
	Hz,		1H)	Hz,						
	1H)			1H)						
Neu5Ac	-	-	2.77 (dd, <i>J</i> =	3.69	3.87	3.66	3.60	4.03	3.70,	2.05 (s,
			12.4, 4.6 Hz,						3.52 –	3H)
			1H), 1.80 (t,						3.49 (m,	
			J = 12.1 Hz,						1H)	
			1H)							

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
Glc	102.01	72.57	74.23	78.14	74.67	59.98	-	-	-	-
Gal	102.53	69.24	75.42	67.24	75.04	60.89	-	-	-	-
Neu5Ac	173.70	99.68	39.58	68.20	51.55	72.68	68.64	70.25	52.94	21.92

Linker	1	2	3
Η	3.47 (t, J = 6.7 Hz, 2H)	1.93 (p, J = 6.5 Hz, 2H)	4.00, 3.78
С	47.75	28.10	67.28



90 was synthesized using sialyltransferase BtST via the general procedure in the methods and white solid after lyophilization (277mg, 82%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{45}N_8O_{18}$, [M-H]⁻: 781.2857, found 781.2856.

¹ H NMR	(600 MHz,	D ₂ O): δ	(ppm)
--------------------	-----------	----------------------	-------

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	
GlcNAc	4.57 (d,	3.82	3.79	3.53	3.50	3.94,	-	-	-	2.06	(s,
	J = 8.3					3.77				3H)	or
	Hz, 1H)									2.04	(s,
										3H)	
Gal	4.50 (d,	3.54	4.08 (dd, J =	3.93	3.68	3.74	-	-	-	-	
	J = 7.8		9.8, 3.2 Hz,			(2H)					
	Hz, 1H)		1H)								
Neu5Ac	-	-	2.76 (dd, J =	3.67	3.85	3.66	3.61 (dd,	3.99	3.67,	2.06	(s,
			12.5, 4.6 Hz,				J = 9.0,		3.52	3H)	or
			1H), 1.79 (t, J				2.0 Hz,			2.04	(s,
			= 12.2 Hz, 1H)				1H)			3H)	

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	100.89	54.47	83.40	68.75	75.39	60.75	-	-	-	22.29 or 22.05
Gal	103.38	69.11	75.65	67.15	75.07	61.02	-	-	-	-
Neu5Ac	173.82	99.63	39.82	68.37	51.64	72.60	68.75	70.57	53.05	22.29 or 22.05

Linker	1	2	3
Н	3.39 (td, J = 6.6, 2.3 Hz, 2H)	1.89 – 1.83 (m, 2H)	3.98, 3.71
С	47.79	28.10	67.15



Synthesis of 92

92 was synthesized using sialyltransferase PPST via the general procedure in the methods and white solid after lyophilization (145 mg, 86%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{45}N_8O_{18}$, [M-H]⁻: 781.2857, found 781.2858.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHA	C
GalNAc	4.52	4.02	3.89	4.18	3.72	3.79,	-	-	-	2.05	or
						3.73				2.04	
Gal	4.51	3.56	4.07	3.94	3.64	3.79,	-	-	-	-	
						3.73					
Neu5Ac	-	-	2.77 (dd, J = 12.5, 4.7	3.69	3.85	3.71	3.60	4.00	3.69,	2.05	or
			Hz), 1.79 (t, $J = 12.2$						3.51	2.04	
			Hz)								

¹H NMR (600 MHz, D₂O): δ (ppm)

¹³C NMR (201 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GalNAc	101.36	51.17	79.94	67.85	74.73	60.93	-	-	-	22.28
Gal	104.53	69.01	75.57	67.27	74.73	60.97	-	-	-	-
Neu5Ac	173.87	99.66	39.77	68.36	51.63	72.57	68.74	70.51	53.02	22.04

Linker	1	2	3
Н	3.40	1.86	3.98, 3.71
С	47.79	28.10	66.99



7 was prepared via the general procedure in the methods and was the white solid after lyophilization (46mg, 58%). ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{29}$ N₄O₁₇S₂, [M-H]^{-:} 625.0975, found 625.0977.

¹ H NMR (600 MI	Hz, D_2O): δ (ppm)								
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.57	3.75	3.75	3.76	3.84	4.44,	-	-	-	2.06
						4.33				
Gal	4.57	3.55 (dd, J = 10.0, 7.8 Hz,	3.70	3.97	3.99	4.21	-	-	-	-
		1H)								
³ C NMR (151 MHz, D ₂ O): δ (ppm)										

		/ - /		/						
	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	101.31	55.06	72.10	78.61	72.50	66.51	-	-	-	22.17
Gal	102.70	70.80	72.26	68.22	72.71	67.04	-	-	-	-

Linker	1	2	3
Н	3.39	1.86	3.97,
			3.70
С	47.77	28.09	67.24



Synthesis of 10

10 was prepared via the general procedure in the methods and was the white solid after lyophilization (27mg, 68%). ESI-Q-TOF-HRMS m/z calculated for $C_{15}H_{27}N_3O_{17}S_2$, [M-H]⁻: 584.0723, found 584.0709. ¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.54	3.40 - 3.34	3.68	3.79	3.88 - 3.83	4.46 – 4.40 (m, 1H),	-	-	-	-
		(m, 1H)			(m, 1H)	4.34 – 4.27 (m, 1H)				
Gal	4.54	3.59 - 3.54	3.72	4.01	4.01	4.26 – 4.20 (m, 2H)	-	-	-	-
		(m, 1H)								

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
Glc	101.96	72.47	74.15	78.67	72.32	66.34	I	-	-	-
Gal	102.82	70.62	72.13	68.10	72.63	67.00	-	-	-	-

Linker	1	2	3
Н	3.51 – 3.45 (m, 2H)	1.96 – 1.90 (m, 2H)	4.01, 3.82 – 3.76 (m, 1H)
С	47.73	28.11	67.38



13 was prepared via the general procedure in the methods and was the white solid after lyophilization (44mg, 55%). ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{29}N_4O_{17}S_2$, [M-H]⁻: 625.0975, found 625.0983. ¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H	H2	H3	H4		H5	H6		H7	H8	H9	NHA	c
GlcNAc	4.58 (d,	J = 3	.87	3.83	3.63	-	3.74	4.41	- 4.3	7 –	-	-	2.06	(s,
	8.3 Hz,	1H)			3.58	(m,		(m,	1H)	,			3H)	
					1H)			4.26						
Gal	4.47 (d,	$J = \begin{vmatrix} 3 \end{vmatrix}$.57 -	- 3.68	3.99		3.97	4.23 ((2H)	-	-	-	-	
	7.8 Hz,	1H) 3	.53 (m	,										
		1	H)											
¹³ C NMR ((151 MHz	z, D ₂ O)	: δ (ppm)										
	C1	C2	C3	C4	C5	C6	C	7 C 8	C9	NHAc				
GlcNAc	103.47	54.53	82.03	68.24	73.21	67.0	8 -	-	-	22.23				
Gal	100.97	70.52	72.28	68.25	72.69	67.1	7 -	-	-	-				

Linker	1	2	3
Η	3.44 – 3.36 (m, 2H)	1.91 – 1.83 (m, 2H)	4.02, 3.71
С	47.81	28.10	67.32



Synthesis of 16

16 was prepared via the general procedure in the methods and was the white solid after lyophilization (44 mg, 79% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for $C_{17}H_{29}N_4O_{17}S_2$, [M-H]⁻: 625.0975, found 625.0978.

		$, D_2 O_{j}.$	o (ppm)								
	H1		H	I 2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.52 (d,	J = 8.6	Hz) 4	.05	3.90	4.24	3.93	4.25	-	-	-	2.05
Gal	4.49 (d,	J = 7.8	Hz) 3	.56	3.66	3.99	3.96	4.20	-	-	-	-
¹³ C NMR ((201 MHz, D ₂ O): δ (ppm)											
	C1	C2	C3	C ₄	4	C5	C6	C7	C8	C)	NHAc

¹H NMR (600 MHz, D₂O): δ (ppm)

GalNAc	101.31	51.12	79.56	67.89	72.43	67.21	-	-	-	22.23
Gal	104.61	70.44	72.31	68.20	72.63	67.89	-	-	-	-

Linker	1	2	3
Н	3.40	1.87	3.98, 3.73
С	47.82	28.12	67.06



17 was synthesized using FucT as described in the methods. White solid after lyophilization (88 mg, yield 72%). ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{39}N_4O_{15}$, [M-H]⁻: 611.2417, found 611.2417.

¹H NMR (600 MHz, D_2O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.55 (d, J	3.90	3.87	3.92	3.60	4.02, 3.85	-	-	-	2.05 (s,
	= 8.1 Hz,									3H)
	1H)									
Gal	4.46 (d, J	3.50 (dd, J	3.66	3.90	3.60	3.73	-	-	-	-
	= 7.8 Hz,	= 9.9, 7.8								
	1H)	Hz, 1H)								
Fuc	5.12 (d, J	3.70	3.90	3.80 (d, J	4.84 (q, J	1.18 (d, J	-	-	-	-
	= 4.0 Hz,			= 3.3 Hz,	= 6.6 Hz,	= 6.6 Hz,				
	1H)			1H)	1H)	3H)				

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	100.95	55.81	74.90	73.36	75.33	59.76	-	-	-	22.22
Gal	101.82	71.03	72.45	68.33	74.90	61.48	-	-	-	-
Fuc	98.63	67.69	69.19	71.90	66.70	15.29	-	-	-	-

Linker	1	2	3
Η	3.38 (q, J = 6.1 Hz, 2H)	1.89 – 1.81 (m, 2H)	3.98, 368
С	47.75	28.10	67.19



Synthesis of 18

18 was synthesized using FucT as described in the methods. White solid after lyophilization (272 mg, yield 69%). ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{39}N_4O_{15}$, [M-H]⁻: 611.2417, found 611.2415.

¹H NMR (500 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.53 (d, J	3.88	4.07 (t, J	3.72	N/R	3.98, 3.86	-	-	-	2.05 (s,
	= 8.5 Hz,		= 9.7 Hz,							3H)

	1H)			1H)											
Gal	4.49 (d,	J 3.48	B (dd, J)	3.62	3	.88	N/R	2	3.	73		-	-	-	-
	= 7.7 Hz	z, = 9	.8, 7.7												
	1H)	Hz,	1H)												
Fuc	5.02 (d,	$J \mid 3.80$)	N/R	N	I/R	4.87	7 (q, J	/ 1.	18 (d,	, J	-	-	-	-
	= 4.0 Hz	z,					= 6.	7 Hz	, =	6.6 E	Iz,				
	1H)						1H)		3F	I)					
¹³ C NMR ((126 MHz	z, D ₂ O):	δ (ppm)									_		
	C1	C2	C3	C4	C5	C	C6	C7	C8	C9	N	HAc			
GlcNAc	101.01	55.74	76.05	72.40	N/R	5	9.67	-	-	-	22	2.25			
Gal	102.86	70.45	72.8	68.33	N/R	6	1.64	-	-	-	-				
Fuc	98.05	67.75	N/R	N/R	66.83	1:	5.34	-	-	-	-				

Linker	1	2	3
Н	3.43 – 3.32 (m, 2H)	1.91 – 1.80 (m, 1H)	3.97, 3.67
С	47.75	28.10	67.17



Synthesis of 19

19 was synthesized using FucT as described in the methods. White solid after lyophilization (27 mg, yield 71%). ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{39}N_4O_{18}S$, [M-H]⁻: 691.1986, found 691.1987.

¹H NMR (500 MHz, D₂O): δ (ppm)

	/	· - /												
	H1		H2		H3	H4	H5	H6		H7	H8	H9	NHA	2
GlcNAc	4.58 (d,	J =	3.90		3.88	4.00	3.81	4.42 -	- 4.34	-	-	-	2.04	(s,
	7.8 Hz, 1H)						(m, 2H)				3H)		
Gal	4.55 (d, $J =$		3.53 -	3.46	3.66	3.91	3.61	3.73		-	-	-	-	
	7.8 Hz, 1H) (m, 1H))											
Fuc	5.12 (d,	J =	3.68		3.90	3.80	4.84	1.18 (d, $J =$	-	-	-	-	
	4.1 Hz, 1	1H)						6.6 Hz,	, 3H)					
¹³ C NMR ((126 MHz	z, D ₂ O)	: δ (ppm))										
	C1	C2	C3	C4			C5		C6	C7	C8	C9	NHAc	;
GlcNAc	100 94	55 69	74 95	72 9	5 or 72	2 77	72 95 0	or 72 77	65 95	_	-	_	22 21	7

GlcNAc	100.94	55.69	74.95	72.95 or 72.77	72.95 or 72.77	65.95	-	-	-	22.21
Gal	101.51	70.98	72.42	68.42	74.78	61.44	-	-	-	-
Fuc	98.59	67.76	69.19	71.90	66.72	15.30	-	-	-	-

Linker	1	2	3
Н	3.42 – 3.33 (m, 2H)	1.89 – 1.79 (m, 2H)	3.97, 3.67
С	47.77	28.10	67.26



94 was synthesized using FucT as described in the methods. White solid after lyophilization (83 mg, yield 66%). ESI-Q-TOF-HRMS m/z calculated for $C_{29}H_{53}N_4O_{15}Si$, [M-H]⁻: 725.3282, found 725.3285.

		H1	H2		H3	H4	H5		H6			H7	H8	H9	NHAc
Gl	lcNAc	4.53 (d,	J 3.92		3.87	3.95	3.57		4.13	(dd, J	<i>I</i> =	-	-	-	2.04 (s,
		= 8.2 Hz	z,						11.9,	2.1 H	łz,				3H)
		1H)							1H),	3.96					
Ga	al	4.49 (d,	J 3.51	(dd, J)	3.64	3.91	3.57		3.73	(2H)		-	-	-	-
		= 7.8 Hz	$z_{,} = 9.$	9, 7.8											
		1H)	Hz,	1H)											
Fu	IC	5.11 (d,	J 3.71		3.91	3.82 -	4.84 (q, J	1.18	(d, J	=	-	-	-	-
		= 4.0 Hz	z,			3.78	= 6.8	Hz,	6.6 H	lz, 3E	I)				
		1H)				(m, 1H)	1H)								
^{13}C	NMR ((151 MHz	z, D ₂ O):	δ (ppm	I)								_		
		C1	C2	C3	C4	C5	C6	C7	C8	C9	N	HAc			
Gl	lcNAc	100.77	55.72	75.01	73.42	2 75.61	61.60	-	-	-	22	2.17			
Ga	al	101.73	70.84	72.45	68.33	3 75.07	61.48	-	-	-	-				
Fu	ıc	98.59	67.64	69.15	71.84	4 66.67	15.26	-	-	-	-]		

¹H NMR (600 MHz, D₂O): δ (ppm)

Linker	1	2	3
Н	3.43 – 3.34 (m, 2H)	1.91 – 1.80 (m, 2H)	3.95, 3.67
С	47.76	28.10	66.95



Synthesis of 20

94 was treated according to the general procedure in the methods to give 20 as the white solid after lyophilization (26 mg, yield 62% for 2 steps). In detail, 94 (44 mg, 0.06 mmol) was dissolved in a mixed solution of 0.5 mL DMF and 0.5 mL TEA. SO₃/Py (39 mg, 0.24 mmol) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then continued to stir at 40 °C for 3 h. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, v/v). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction. Subsequently, the reaction crude was treated according to the general procedure in the methods to deprotect the TBDMS group to give 20.

ESI-Q-TOF-HRMS m/z calculated for $C_{23}H_{39}N_4O_{18}S$, [M-H]⁻: 691.1986, found 691.1986.

$\frac{111111111}{100000000000000000000000000$										
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.55 (d, J	2.88	3.86	3.94	3.63 –	4.01, 3.86	-	-	-	2.05 (s,
	= 7.8 Hz,				3.58 (m,					3H)
	1H)				1H)					
Gal	4.48 (d, J	3.52 (dd, J	3.68	3.96	N/R	4.20 –	-	-	-	-
	= 7.9 Hz,	= 9.9, 7.8				4.11 (m,				

¹H NMR (600 MHz, D₂O): δ (ppm)

	1H)	Hz, 1H)				21	H)				
Fuc	5.11 (d,	J 3.66	3.90	3.81 (d, J	4.84	1.	19 (d, J	-	-	-	-
	= 4.0 Hz	Z,		= 3.3 Hz,		=	6.6 Hz,				
	1H)			1H)		31	H)				
¹³ C NMR (151 MHz, D ₂ O): δ (ppm)											
	C1	C2	C3	C4		C5	C6	C7	C8	C9	NHAc
GlcNAc	100.93	55.84	75.09	73.73		75.37	59.86	-	-	-	22.22
Gal	101.77	70.92		67.85 or	67.80	N/R	66.94	-	-	-	-
Fuc	98.57	67.85 or 67.80	69.13	N/R		66.69	15.32	-	-	-	-

Linker	1	2	3
Н	3.43 – 3.34 (m, 2H)	1.90 – 1.81 (m, 2H)	3.96, 3.66
С	47.75	28.10	67.13

N/R: not reported.



Synthesis of 95

95 was synthesized using sialyltransferase PPST via the general procedure in the methods and white solid after lyophilization (191mg, 63%). ESI-Q-TOF-HRMS m/z calculated for $C_{34}H_{55}N_8O_{22}$, [M-H]⁻: 927.3436, found 927.3432.

<u>III (Mill (000 Millz, D20): 0 (ppill)</u>										
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.52	3.90	3.85	3.95	3.58	4.02,	-	-	-	2.04 (s,
						3.89				6H)
Gal	4.51	3.53	4.07	3.92	N/R	3.69	-	-	-	-
Fuc	5.11 (d,	3.67	3.90	3.78 (d,	4.82	1.17 (d, J	-	-	-	-
	J = 4.0			J = 3.9		= 6.6 Hz,				
	Hz, 1H)			Hz, 1H)		2H)				
Neu5Ac	-	-	$2.76 (\mathrm{dd}, J =$	3.67	3.86	N/R	N/R	4.03	3.69,	2.04 (s,
			12.4, 4.6						3.50	6H)
			Hz, 1H),							
			178							

¹H NMR (600 MHz, D₂O): δ (ppm)

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	100.96	55.80	N/R	73.31	N/R	59.68	-	-	-	22.21 or 22.03
Gal	101.58	N/R	75.71	67.23	N/R	61.46	-	-	-	-
Fuc	98.58	N/R	N/R	71.88	66.67	15.25	-	-	-	-
Neu5Ac	173.82	99.65	39.85	N/R	51.67	N/R	N/R	70.46	53.09	22.21 or 22.03

Linker	1	2	3
Н	3.43 – 3.32 (m, 2H)	1.85 (q, J = 6.3 Hz, 2H)	3.97, 3.68
С	47.75	28.10	67.17

N/R: not reported.


21 was prepared via the general procedure in the methods and was the white solid after lyophilization (22mg, 52% for 2 steps). ESI-Q-TOF-HRMS m/z calculated for C₂₃H₃₉N₄O₂₁S₂, [M-H]⁻: 771.1554, found 771.1552.

	000 WII1Z,	D_2O_2 .	$\cdot \circ (ppm)$											
	H1		H2		H3	H4	H5	H6		H7	H8	H9	NHA	c
GlcNAc	4.56 (d,	$J = \begin{bmatrix} 1 \\ 1 \end{bmatrix}$	3.87		3.87	3.86	3.80	4.41	- 4.3	4 -	-	-	2.02	(s,
	7.9 Hz, 1	H)						(m, 2	2H)				3H)	
Gal	4.53 (d,	$J = \begin{bmatrix} 1 \\ 1 \end{bmatrix}$	3.49 (dd	I, J =	3.67	3.95	N/R	4.18	- 4.1	0 -	-	-	-	
	7.8 Hz, 1	(H)	9.9, 7.8	8 Hz,				(m, 2	2H)					
			1H)											
Fuc	5.08 (d,	J = 1	3.63		3.88	3.79	4.81	1.16	(d, <i>J</i>	= -	-	-	-	
	4.0 Hz, 1	H)						6.7 H	Iz, 2H)				
¹³ C NMR ((151 MHz	(D_2O)): δ (ppm	.)										
	C1	C2	C3	C4	C5	C6	C	7 C8	C9	NHAc]			
GlcNAc	100.92	55.69	74.99	73.42	73.06	66.0	07 -	-	-	22.21				

_

-

_

_

-

-

66.78

15.33

-

_

¹H NMR (600 MHz D_2O). δ (ppm)

101.70

98.66

70.84

67.87

N/R

69.11

Linker	1	2	3
Н	3.41 – 3.30 (m, 2H)	1.83 (qp, J = 7.9, 2.1 Hz, 2H)	3.95, 3.65
С	47.76	28.10	67.23

67.87

N/R

N/R

66.70

N/R: not reported.

Gal

Fuc



Synthesis of 99

99 was synthesized using FucT as described in the methods. White solid after lyophilization (80 mg, yield 80%). ESI-Q-TOF-HRMS m/z calculated for C₂₉H₅₃N₄O₁₅Si, [M-H]⁻: 725.3282, found 725.3283.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.51 (d,	3.87	4.06 (t, J	3.66	N/R	$4.15 (\mathrm{dd}, J =$	-	-	-	2.05 (s,
	J = 8.6		= 9.7			11.8, 2.2				3H)
	Hz, 1H)		Hz, 1H)			Hz, 1H),				
						3.94				
Gal	4.49 (d,	3.49 (dd, J	N/R	3.87	N/R	3.75 - 3.72	-	-	-	-
	J = 7.7	= 9.9, 7.7				(m, 2H)				
	Hz, 1H)	Hz, 1H)								

¹H NMR (600 MHz, D_2O): δ (ppm)

0.02 (d	, 3.79		3.87	N/R	4.87	(q,	1.18	(d, J)	=	-	-	-	-
V = 4.0)				J =	6.6	6.6 H	Iz, 3F	I)				
Hz, 1H)					Hz, 1	H)							
51 MHz	z, D ₂ O):	δ (ppm)										
C1	C2	C3	C4	C5	C6	C7	C8	C9	N	HAc			
02.81	55.74	76.09	73.33	N/R	61.82	-	-	-	22	.22			
00.95	70.39	N/R	68.32	N/R	61.67	-	-	-	-				
98.38	67.65	N/R	N/R	66.83	15.35	-	-	-	-				
	= 4.0 $= 4.0$ $1 MHz$ $1 MHz$ 02.81 00.95 8.38	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Linker	1	2	3
Н	3.39 (td, J = 6.5, 2.9 Hz, 2H)	1.90 – 1.81 (m, 2H)	3.96, 3.68
С	28.10	47.78	67.06



Synthesis of 22

99 was treated according to the general procedure in the methods to give **22** as the white solid after lyophilization (37 mg, yield 54% for 2 steps). In detail, **99** (72 mg, 0.10 mmol) was dissolved in a mixed solution of 0.5 mL DMF and 0.5 mL TEA. SO₃/Py (63 mg, 0.40 mmol) was then added under an ice bath. The reaction was stirred for 15 min at 0 °C and then continued to stir at 40 °C for 3 h. Monitoring reaction by TLC (EtOAc/MeOH/H₂O, 10:3:2, *v/v*). Methanol and saturated NaHCO₃ aqueous were poured into the reaction mixture to quench the reaction. Subsequently, the reaction crude was treated according to the general procedure in the methods to deprotect the TBDMS group to give **22**. ESI-Q-TOF-HRMS m/z calculated for C₂₃H₃₉N₄O₁₈S, [M-H]⁻: 691.1986, found 691.1986.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.48	3.89	4.07 –	3.69	3.55	3.98, 3.86	-	-	-	2.03 (s,
			4.02							3H)
			(m, 1H)							
Gal	4.49	3.47 (dd, J	3.63	3.92	3.91	4.19 - 4.14	-	-	-	-
		= 9.8, 7.8				(m, 1H), 4.14				
		Hz, 1H)				– 4.10 (m,				
						1H)				
Fuc	4.99 (d,	3.75 (dd, J	N/R	N/R	4.90 –	1.16 (d, J =	-	-	-	-
	J = 4.0	= 10.5, 4.0			4.83	6.6 Hz, 3H)				
	Hz, 1H)	Hz, 1H)			(m, 1H)					

¹H NMR (600 MHz, D₂O): δ (ppm)

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	100.63	55.22	75.82	72.14	74.90	59.16	-	-	-	21.80
Gal	102,31	69.87	71.59	67.48	68.56	67.07	-	-	-	-
Fuc	97.68	67.48	N/R	N/R	66.35	14.93	-	-	-	-

Linker	1	2	3
Н	3.41 – 3.31 (m, 2H)	1.85 – 1.79 (m, 2H)	3.95, 3.66
С	47.31	27.66	66.74



Synthesis of 27

27 was synthesized using Pd2,6ST as described in the methods. White solid after lyophilization (23 mg, yield 74%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{46}N_5O_{22}S$, [M-H]⁻: 836.2361, found 836.2362. ¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.59 (d, J	3.76	3.79	3.69	3.85	4.46,	-	-	-	2.08 or
	= 7.8 Hz,					4.30				2.04
	1H)									
Gal	4.50 (d, J	3.54	3.69	3.94	3.85	4.01,	-	-	-	-
	= 7.9 Hz,					3.54				
	1H)									
Neu5Ac	-	-	2.67 (dd, $J = 12.4$,	3.67	3.81	3.76	3.56	3.91	3.90,	2.08 or
			4.6 Hz, 1H), 1.72						3.66	2.04
			(t, J = 12.2 Hz, 1H)							

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	C9	NHAc
GlcNAc	100.96	54.78	72.32	80.34	72.52	66.77	-	-	-	22.27 or 22.00
Gal	103.42	70.74	72.37	68.35	73.62	63.26	-	-	-	-
Neu5Ac	173.51	100.12	40.07	68.21	51.87	72.37	68.39	71.66	62.63	22.27 or 22.00

Linker	1	2	3
Н	3.40	1.87	3.99, 3.72
С	47.78	28.10	67.24



Synthesis of 28

28 was synthesized using Pd2,6ST as described in the methods. White solid after lyophilization (22 mg, yield 92%). ESI-Q-TOF-HRMS m/z calculated for $C_{26}H_{43}N_4O_{22}S$, [M-H]^{-:} 795.2095, found 795.2098.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.58	3.87	3.81	3.57	3.74	4.41, 4.24	-	-	-	2.08 –
	(d, J =					(dd, J =				2.01 (m,
	8.4 Hz,					11.3, 5.9				6H)

	1H)					Hz, 1H)				
Gal	4.41	3.52 (dd,	3.65	3.93	3.74	3.95, 3.63	-	-	-	-
		J = 10.0,								
		7.8 Hz,								
		1H)								
Neu5Ac	-	-	2.73 (dd, $J =$	3.69	3.82	3.79	3.58	3.89	3.89,	2.08 -
			12.4, 4.6 Hz,						3.65	2.01 (m,
			1H), 1.71 (t,							6H)
			J = 12.2 Hz,							
			1H)							

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	C8	С9	NHAc
GlcNAc	100.94	54.40	82.75	68.16	72.56	67.27	-	-	-	22.22 or 22.01
Gal	103.72	70.54	72.36	68.45	73.25	63.38	-	-	-	-
Neu5Ac	173.47	100.37	40.19	68.28	51.95	73.44	68.67	71.73	62.62	22.22 or 22.01

Linker	1	2	3
Н	3.43 – 3.35 (m, 2H)	1.91 – 1.81 (m, 2H)	3.99, 3.72
С	47.80	28.10	67.30



Synthesis of 29

Neu5Ac

173.47

100.37

40.19

29 was synthesized using Pd2,6ST as described in the methods. White solid after lyophilization (14 mg, yield 93%). ESI-Q-TOF-HRMS m/z calculated for $C_{28}H_{46}N_5O_{22}S$, [M-H]⁻: 836.2361, found 836.2365.

``````````````````````````````````````	H1	H2	H3		H4	H5	H6	H	7	H8	H9	NHAc
GlcNAc	4.58	3.87	3.81	l	3.57	3.74	4.41, 4.24	4 -		-	-	2.08 -
	(d, J =						(dd, J =	=				2.01 (m,
	8.4 Hz,						11.3, 5.	9				6H)
	1H)						Hz, 1H)					
Gal	4.41	3.52 (dd	3.65	5	3.93	3.74	3.95, 3.6	3 -		-	-	-
		J = 10.0										
		7.8 Hz										
		1H)										
Neu5Ac	-	-	2.73	$\mathcal{B}$ (dd, $J$	= 3.69	3.82	3.79	3.	58	3.89	3.89,	2.08 –
			12.4	4, 4.6 Hz	z,						3.65	2.01 (m,
			1H)	, 1.71 (	t,							6H)
			J =	12.2 Hz	Ζ,							
			1H)									
$^{13}C$ NMR (	(151 MHz	z, D ₂ O): δ	(ppm)									
	C1	C2	C <b>3</b>	C4	C5	<b>C6</b>	C7 C	C <b>8</b>	C	9	NHAc	
GlcNAc	100.94	54.40	32.75	68.16	72.56	67.27			-		22.22 or	22.01
Gal	103.72	70.54	72.36	68.45	73.25	63.38			-		-	

¹H NMR (600 MHz, D₂O): δ (ppm)

73.44

68.67

68.28 51.95

62.62

71.73

22.22 or 22.01

Linker	1	2	3
Η	3.43 – 3.35 (m, 2H)	1.91 – 1.81 (m, 2H)	3.99, 3.72



**30** was synthesized using Pd2,6ST as described in the methods. White solid after lyophilization (10.7 mg, 71%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2361. ¹H NMR (500 MHz, D₂O):  $\delta$  (npm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.51 (d, J	4.03	3.92	4.21	3.96	4.25	-	-	-	2.04
	= 8.5 Hz)									
Gal	4.45 (d, J	3.51	3.62	3.94	3.73	3.90,	-	-	-	-
	= 7.8 Hz)					3.66				
Neu5Ac	-	-	2.75  (dd,  J = 12.5,	3.69	3.83	3.73	3.60	3.89	3.90,	2.04
			4.7 Hz), 1.69 (t, <i>J</i> =						3.66	
			12.1 Hz)							

$-\mathbf{V} + \mathbf{N} + \mathbf{V} +$	¹³ C NMR	(126  MHz)	$D_2(\Omega) \cdot \delta$	(ppm)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------	------------	----------------------------	-------

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GalNAc	101.29	51.14	79.26	67.74	72.60	67.71	-	-	-	22.18
Gal	104.52	70.41	72.53	N/R	73.07	63.17	-	-	-	-
Neu5Ac	173.38	100.47	40.14	N/R	51.82	72.26	N/R	71.66	62.55	21.94

Linker	1	2	3
Н	3.40	1.86	3.98, 3.73
С	47.75	28.06	67.12



## Synthesis of 31

**31** was synthesized using Pd2,6ST as described in the methods. White solid after lyophilization (20 mg, 65%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2360.

	H1	H2	H3				H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.48	4.01	3.88				4.17	3.75	3.98	-	-	-	2.04
Gal	4.47	3.53	3.64				3.96	3.80	4.18	-	-	-	-
Neu5Ac	-	-	2.75	(dd, J	= 12.4, 4	4.6 Hz),	3.68	3.83	3.72	3.58	3.90	3.89,	2.04
			1.74	(t, J = 1)	12.2 Hz)							3.65	
¹³ C NMR (	126 M	Hz, D	2O): δ	(ppm)									
	<b>C1</b>	C2	2	<b>C3</b>	C4	C5	<b>C6</b>	<b>C7</b>	(	C <b>8</b>	<b>C9</b>	NHA	c
GalNAc	101 4	3 51	22	79 32	68 24	73 26	63 69	_	-		_	22.22	or

## ¹H NMR (500 MHz, D₂O): δ (ppm)

										22.01	
Gal	104.57	70.43	72.27	68.24	72.58	67.27	-	-	-	-	
Neu5Ac	173.41	100.37	40.07	68.16	51.83	72.39	68.16	71.60	62.62	22.22	or
				or			or			22.01	
				68.06			68.06				

Linker	1	2	3
Н	3.39	1.86	3.99, 3.70
С	47.77	28.14	66.94



**32** was synthesized using BtST as described in the methods. White solid after lyophilization (730 mg, yield 90%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{19}$ , [M-H]⁻: 756.2792, found 756.2792.

1 H NMR (	¹ H NMR (600 MHz, $D_2O$ ): $\delta$ (ppm)											
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc		
GlcNAc	4.53 (d, <i>J</i> =	3.75	3.70	3.74	3.60	4.01,	-	-	-	2.05 or		
	7.8 Hz, 1H)					3.87				2.04		
Gal	4.55 (d, $J =$	3.58	4.12	3.98	3.69	3.74	-	-	-	-		
	8.0 Hz, 1H)											
Neu5Ac	-	-	2.76 (dd, J =	3.69	3.85	3.75	3.59	3.90	3.65	2.05 or		
			12.4, 4.2 Hz,							2.04		
			1H), 1.82									

¹³ C NMR	(151	MHz.	$D_2O)$	:δ	(ppm)	)
• · · · · · · · · · · · · · · · · · · ·			- 201	•••	( P P )	

	ì	<u> </u>		í	I	1	1		1	1
	<b>C1</b>	C2	<b>C3</b>	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	101.12	55.06	72.31	78.29	74.72	60.01	-	-	-	22.14
Gal	102.54	69.36	75.44	67.45	75.13	60.99	-	-	-	-
Neu5Ac	173.68	99.70	39.55	68.07	51.65	72.88	68.27	71.68	62.58	22.14

Linker	1	2	3
Н	3.38	1.85	3.99, 3.69
С	47.75	28.08	67.11



#### Synthesis of 33

**33** was synthesized using BtST as described in the methods. White solid after lyophilization (130 mg, yield 77%). ESI-Q-TOF-HRMS m/z calculated for  $C_{26}H_{43}N_4O_{19}$ , [M-H]^{-:} 715.2527, found 715.2524.

¹ H NMR	(800 MHz,	D ₂ O): δ	(ppm)
--------------------	-----------	----------------------	-------

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.49 (d,	3.34 –	3.64	3.66	3.60	4.00,	-	-	-	-

	J = 8.1	3.29				3.83				
	Hz, 1H)	(m,								
		1H)								
Gal	4.54 (d,	3.58	4.12 (dd, $J =$	3.96 (d,	3.72	3.74	-	-	-	-
	J = 7.9		9.9, 3.1 Hz,	J = 3.1		(2H)				
	Hz, 1H)		1H)	Hz, 1H)						
Neu5Ac			2.76  (dd,  J =	3.69	3.84	3.64	3.60	3.89	3.87,	2.04 (s,
			12.5, 4.6 Hz,						3.64	3H)
			1H), 1.81 (t, J							
			= 12.2 Hz, 1H)							

#### ¹³C NMR (201 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
Glc	102.01	72.75	74.22	78.13	74.65	59.93	-	-	-	-
Gal	102.52	69.24	75.36	67.24	75.04	60.90	-	-	-	-
Neu5Ac	173.72	99.65	39.50	68.22	51.55	72.68	67.97	71.63	62.45	21.90

Linker	1	2	3
Н	3.47 (t, J = 6.7 Hz, 2H)	1.94 – 1.89 (m, 2H)	4.00, 3.77
С	47.75	28.10	67.33



## Synthesis of 34

**34** was synthesized using BtST as described in the methods. White solid after lyophilization (110 mg, yield 68%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{19}$ , [M-H]⁻: 756.2792, found 756.2794.

Ì	H1	H2	H3		H4	H5		H6		H7	H8	H9	NHA	c
GlcNAc	4.57 (d,	3.82	3.79		3.55	3.51	_	3.94	4,	-	-	-	2.10	_
	J = 8.3					3.47		3.70	6				2.00	(m,
	Hz, 1H)					(m,							6H)	
						1H)								
Gal	4.51 (d,	3.55	4.09	(dd, J =	= 3.95	3.69		3.7	5	-	-	-	-	
	J = 7.8		9.8, 3.	2 Hz, 1H)	)									
	Hz, 1H)													
Neu5Ac	-	-	2.77	(dd, J =	= 3.55	3.84		3.6	5	3.61	3.88	3.85,	2.10	_
			12.4,	4.6 Hz	,							3.65	2.00	(m,
			1H), 1	.79 (t, J=	=								6H)	
			12.1 H	Iz, 1H)										
¹³ C NMR (	(151 MHz,	, D ₂ O):	δ (ppm	)		•						•		
	C1	C2	C3	C4 (	C <b>5</b>	C6	<b>C7</b>	,	<b>C8</b>	C	9	NHAc		]

¹ H NMR	(600 MHz	$D_2(0)$	· 8	(nnm)	)
		$D_{2}O_{1}$		(ppm)	1

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	100.91	54.44	82.52	68.04	75.09	60.74	-	-	-	22.31 or 22.04
Gal	103.45	69.08	75.62	67.25	75.39	61.01	-	-	-	-
Neu5Ac	173.90	99.65	39.77	69.39	51.66	72.80	68.74	71.84	62.45	22.31 or 22.04

Linker	1	2	3
Н	3.39 (td, J = 6.6, 2.4 Hz, 2H)	1.90 – 1.82 (m, 2H)	3.99 (dt, <i>J</i> = 10.9, 5.6 Hz, 1H), 3.71





**35** was synthesized using BtST as described in the methods. White solid after lyophilization (145 mg, 90%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{19}$ , [M-H]⁻: 756.2792, found 756.2795.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	2
GalNAc	4.53	4.03	3.88	4.19	3.72	3.74	-	-	-	2.05	or
										2.04	
Gal	4.54	3.56	4.09	3.95	3.65	3.74	-	-	-	-	
Neu5Ac	-	-	2.76 (dd, J = 12.4, 4.2 Hz),	3.65	3.86	3.74	3.62	3.89	3.86,	2.05	or
			1.79 (t, J = 12.1  Hz)						3.66	2.04	

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	<b>C2</b>	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	С9	NHAc
GalNAc	101.39	51.14	80.02	67.84	74.75	60.93	-	-	-	22.29
Gal	104.57	68.98	75.54	67.34	74.72	60.97	-	-	-	-
Neu5Ac	173.91	99.66	39.71	68.03	51.65	72.77	68.37	71.80	62.46	22.03

Linker	1	2	3
Н	3.40	1.87	3.99, 3.72
С	47.78	28.10	66.99



## Synthesis of 38

**38** was synthesized using BtST as described in the methods. White solid after lyophilization (68 mg, yield 88%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2363.

|--|

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.55 (d, J =	3.75	3.70	3.79	3.79	4.39,	-	-	-	2.03 or
	8.2 Hz,					4.31				2.01
	1H)									
Gal	4.62 (d, J =	3.56	4.12	3.95	3.70	3.72	-	-	-	-
	7.8 Hz,									
	1H)									
Neu5Ac	-	-	2.75 (dd, J =	3.68	3.83	3.70	3.58	3.90	3.87,	2.03 or
			12.4, 4.7 Hz,						3.64	2.01
			1H), 1.80							
¹³ C NMR	(151 MHz D	$\overline{O}$ $\delta$	nnm)				•			

0 1 11111 (	1011111	$ , \boldsymbol{\nu}_2  $	o (ppm	/						
	C1	<b>C2</b>	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	101.17	55.05	72.20	77.16	72.50	66.25	-	-	-	22.15

Gal	102.09	69.44	75.30	67.45	75.05	61.02	-	-	-	-
Neu5Ac	173.95	99.72	39.56	68.04	51.68	72.81	68.43	71.47	62.49	22.03

Linker	1	2	3
Н	3.36	1.83	3.96, 3.67
С	47.76	28.08	67.24



**39** was synthesized using BtST as described in the methods. White solid after lyophilization (35 mg, yield 76%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2360.

¹ H NMR	(600 MHz,	D ₂ O):	δ (ppm)
--------------------	-----------	--------------------	---------

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.53 (d, <i>J</i> =	3.75	3.74	3.72	3.64	4.02,	-	-	-	2.06
	7.4 Hz, 1H)					3.86				or
										2.04
Gal	4.61 (d, <i>J</i> =	3.60	4.14	4.02	3.98	4.19	-	-	-	-
	7.9 Hz, 1H)									
Neu5Ac	-	-	2.77 (dd, $J = 12.4$ ,	3.71	3.87	3.75	3.60	3.91	3.89,	2.06
			4.2 Hz, 1H), 1.82						3.66	or
										2.04

#### ¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	101.12	55.13	72.03	79.13	74.68	60.26	-	-	-	22.16
Gal	102.36	69.25	75.20	67.35	72.69	67.40	-	-	-	-
Neu5Ac	173.80	99.94	39.49	68.08	51.64	72.87	68.37	71.69	62.56	22.16

Linker	1	2	3
Н	3.39	1.85	3.98, 3.67
С	47.75	28.08	67.08



#### Synthesis of 40

**40** was synthesized using PPST as described in the methods. White solid after lyophilization (18 mg, yield 82%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{25}S_2$ , [M-H]⁻: 916.1929, found 916.1929.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.56	3.75	3.77	3.77	3.85	4.46,4.32	-	-	-	2.06
										or
										2.05

Gal	4.64 (d,	J = 3	8.47 4.	16		4.04	3.98	4.2	20	-	-	-	-
	7.9 Hz,	1H)											
Neu5Ac	-	-	2.	76 (dd,	J =	3.68	3.88	3.′	71	3.60	3.93	3.91,	2.06
			12	2.4, 4.6	Hz,							3.66	or
			11	H), 1.81									2.05
¹³ C NMR (	(151 MHz	$z, D_2O)$	): δ (ppn	1)									
	C1	<b>C2</b>	<b>C3</b>	C4	C5	C6	<b>C7</b>		<b>C8</b>	С9	]	NHAc	
GlcNAc	101.15	55.07	72.00	78.63	72.52	66.63	3 –		-	-	,	22.17	
Gal	102.28	69.31	75.06	67.32	72.56	67.31	-		-	-		-	
Neu5Ac	173.91	99.91	39.45	68.10	51.66	72.82	2 68.5	50	71.53	62.52		22.05	

Linker	1	2	3
Н	3.39	1.85	3.97, 3.67
С	47.78	28.09	67.24



**41** was synthesized using BtST as described in the methods. White solid after lyophilization (20 mg, yield 83%). ESI-Q-TOF-HRMS m/z calculated for  $C_{26}H_{43}N_4O_{22}S$ , [M-H]⁻: 795.2095, found 795.2094.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3		H4	H5	H6		H7		H8	H	)	NHAc
Glc	4.51	3.34	3.66		3.76	3.82	4.40	) (dd, J	/ _		-	-		-
	(d, J =	(dd, $J$					= 1	1.1, 2.1						
	8.0	= 9.5,					Hz,	1H),						
	Hz,	8.0 Hz,					4.32	2 (dd, J						
	1H)	1H)					= 1	1.0, 4.4						
							Hz,	1H)						
Gal	4.61	3.56	4.13	(dd, J	3.97	3.72	3.75	5 (2H)	-		-	-		-
	(d, J =	(dd, $J$	= 9.9	9, 3.2										
	7.9	= 9.9,	Hz, 1	H)										
	Hz,	7.9 Hz,												
	1H)	1H)												
Neu5Ac	-	-	2.76	(dd, J	3.69	3.86	3.64	1	3.61		3.95	-   3.9	90,	2.04 (s,
			= 12.	4, 4.6					(dd,	J	3.91	3.6	66	3H)
			Hz,	1H),					=	9.1,	(m,			
			1.82	(t, J =					1.8	Hz,	1H)			
			12.1	Hz,					1H)					
			1H)											
¹³ C NMR (	(150 MH	z, D ₂ O):	δ (ppm	)									-	
	C1	C2	C3	C4	C5	C6	5	C7	C8	<b>C9</b>	N	HAc		
Glc	102.00	72.70	74.06	76.87	72.3	7   66.	.06   -	-	-	-	-			

Glc	102.00	72.70	74.06	76.87	72.37	66.06	-	-	-	-
Gal	102.07	69.30	75.19	67.37	74.90	60.88	-	-	-	-
Neu5Ac	173.72	99.52	39.40	68.27	51.54	72.56	67.92	71.28	62.38	21.89

Н	3.49 – 3.44 (m, 2H)	1.95 – 1.89 (m, 2H)	4.00, 3.78
С	47.73	28.10	67.31



**42** was synthesized using BtST as described in the methods. White solid after lyophilization (26 mg, yield 81%). ESI-Q-TOF-HRMS m/z calculated for  $C_{26}H_{43}N_4O_{22}S$ , [M-H]⁻: 795.2095, found 795.2090.

¹ H NMR (	600 MHz,	D ₂ O):	δ (ppm)	)									
	H1	H2	H3	6		H4	H5	He	6	H7	H8	H9	NHAc
Glc	4.51 (d,	3.37	- 3.6	6		3.65	3.63	4.0	)0,	-	-	-	-
	J = 8.0	3.32						3.8	33				
	Hz, 1H)	(m,											
		1H)											
Gal	4.57 (d,	3.60	4.1	5 (dd,	J =	4.03	3.99	4.2	24 –	-	-	-	-
	J = 7.9		9.9	9, 3.1 Hz	z, 1H)			4.1	8				
	Hz, 1H)							(m	, 2H)				
Neu5Ac	-	-	2.7	'7 (dd,	J =	3.71	3.87	3.6	55	3.61	3.90	3.90,	2.05 (s,
			12.	5, 4.6	Hz,							3.66	3H)
			1H	), 1.82 (	[t, J = ]								
			12.	1 Hz, 1	H)								
¹³ C NMR (	(151 MHz	, D ₂ O):	δ (ppm	.)									
	C1	C2	C3	C4	C5	C6	(	27	<b>C8</b>	<b>C9</b>	N	HAc	
Glc	101.90	72.61	72.19	79.35	74.53	60.1	13 -		-	-	-		
Gal	102.65	69.07	75.06	67.20	72.75	67.3	36 -		-	-	-		

71.58 62.45

21.91

Linker	1	2	3
Н	3.47 (t, J = 6.7 Hz, 2H)	1.96 – 1.89 (m, 2H)	3.99, 3.78 (dt, $J = 10.3, 6.2$ Hz, 1H)
С	47.74	28.10	67.23

51.54

72.61

67.97



## Synthesis of 43

Neu5Ac

173.72

99.83

39.37

68.26

**43** was synthesized using PPST as described in the methods. White solid after lyophilization (17 mg, yield 57%). ESI-Q-TOF-HRMS m/z calculated for  $C_{26}H_{43}N_4O_{25}S_2$ , [M-H]⁻: 875.1663, found 875.1661.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.51	3.35	3.67	3.70	3.83	4.43 (dd, $J =$	-	-	-	-
	(d, J =	(dd, J =				11.2, 2.1 Hz,				
	8.0 Hz,	9.1, 8.0				1H), 4.29				
	1H)	Hz, 1H)				(dd, J = 11.2,				

¹H NMR (500 MHz, D₂O): δ (ppm)

						5.2 Hz, 1H)				
Gal	4.61	3.57	$4.16 (\mathrm{dd}, J =$	4.03	3.98	4.19 (2H)	-	-	-	-
	(d, J =		10.0, 3.2							
	7.9 Hz,		Hz, 1H)							
	1H)									
Neu5Ac			$2.75 (\mathrm{dd}, J =$	3.70	3.85	3.64	3.59	3.91	3.88,	2.03 (s,
			12.4, 4.6						3.64	3H)
			Hz, 1H),							
			1.82 (t, $J =$							
			12.1 Hz,							
			1H)							
¹³ C NMR (	(126 MHz	z, D ₂ O): δ	(ppm)							

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
Glc	101.94	72.69	74.09	78.67	72.31	66.39	-	-	-	-
Gal	102.47	69.11	74.90	67.18	72.47	67.37	-	-	-	-
Neu5Ac	173.64	99.68	39.27	68.31	51.52	72.44	67.95	71.32	62.39	21.90

Linker	1	2	3
Н	3.47 (t, J = 6.7 Hz, 2H)	1.96 – 1.87 (m, 2H)	3.98, 3.82 – 3.74 (m, 1H)
С	47.72	28.10	67.20



**44** was synthesized using BtST as described in the methods. White solid after lyophilization (12.5 mg, yield 83%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2364.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.59 (d,	3.84	3.81	3.61	3.73	4.38 (dd, J =	-	-	-	2.05 -
	J = 8.3					11.3, 2.2 Hz,				2.03 (m,
	Hz,					1H), 4.23 (dd,				6H)
	1H)					J = 11.3, 5.7				
						Hz, 1H)				
Gal	4.51 (d,	3.54	$4.10 (\mathrm{dd}, J =$	3.94	3.68	3.73 (2H)	-	-	-	-
	J = 7.8		9.8, 3.2 Hz,							
	Hz,		1H)							
	1H)									
Neu5Ac	-	-	$2.77 (\mathrm{dd}, J =$	3.71	3.86	3.65	3.60	3.88	3.86,	2.05 –
			12.4, 4.6 Hz,						3.65	2.03 (m,
			1H), 1.83 –							6H)
			1.77 (m, 1H)							

¹H NMR (600 MHz, D₂O): δ (ppm)

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	<b>C3</b>	C4	C5	C6	<b>C7</b>	<b>C8</b>	С9	NHAc
GlcNAc	100.41	53.92	81.68	67.53	72.29	66.78	-	-	-	21.78, 21.52
Gal	102.96	68.57	75.08	67.53	74.55	60.49	-	-	-	-
Neu5Ac	173.17	99.00	39.17	68.00	51.12	72.77	67.80	71.23	61.96	21.78, 21.52

Linker	1	2	3
Н	3.43 – 3.35 (m, 2H)	1.90 – 1.83 (m, 2H)	3.99, 3.70
С	47.28	27.59	66.78



**45** was synthesized using BtST as described in the methods. White solid after lyophilization (14 mg, yield 61%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2362.

	H1	H2	H3		H4	H5		H6		H7	H8	H9	NHAc	
GlcNAc	4.56 (d,	3.84	3.77		3.5	4 3.5	0	3.93,		-	-	-	2.05	(s,
	J = 8.5							3.78					3H)	or
	Hz, 1H)												2.04	(s,
													3H)	
Gal	4.52 (d,	3.54	4.12	(dd, J)	= 4.0	0 3.9	5	4.23	_	-	-	-	-	
	J = 7.9		9.8, 3.	2 Hz, 1H				4.15						
	Hz, 1H)							(m, 2E	I)					
Neu5Ac	-	-	2.76	(dd, J)	= 3.6	9 3.8	6	3.64		3.60	3.88	3.86,	2.05	(s,
			12.4,	4.6 H	z,							3.65	3H)	or
			1H), 1	.80 (t, J	=								2.04	(s,
			12.1 H	(z, 1H)									3H)	
¹³ C NMR (	(151 MHz	z, D ₂ O):	δ (ppm	)										
	C1	C2	C3	C4	C5	C6		C7	C	8	C9	NHAc		
GlcNAc	100.89	51.64	83.22	68.40	75.36	60.69	) .	-	-		-	22.27 o	r 22.02	
Gal	103.55	68.93	75.34	67.20	72.70	67.62	2 .	-	-		-	-		
Neu5Ac	173.82	99.77	39.63	68.93	54.31	72.79	) (	68.03	71	1.77	62.46	22.27 o	r 22.02	

¹H NMR (600 MHz, D₂O): δ (ppm)

Linker	1	2	3
Η	3.44 – 3.34 (m, 2H)	1.89 – 1.83 (m, 2H)	3.96, 3.70
С	47.78	28.08	67.13



## Synthesis of 46

**46** was synthesized using PPST as described in the methods. White solid after lyophilization (15 mg, yield 52%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{25}S_2$ , [M-H]⁻: 916.1929, found 916.193.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.58	3.85	3.81	3.60	3.73	4.39 (dd, J =	-	-	-	2.09 –
	(d, J =					11.2, 2.1 Hz,				1.99 (m,
	8.3 Hz,					1H), 4.24 (dd,				6H)

	1H)					J = 11.3, 5.8					
						Hz, 1H)					
Gal	4.53	3.56	4.12 (dd, $J =$	4.00	3.94	4.22 - 4.16	-	-	-	-	
	(d, J =		9.8, 3.2 Hz,			(m, 2H)					
	7.8 Hz,		1H)								
	1H)										
Neu5Ac	-	-	2.77 (dd, $J =$	3.69	3.87	3.65	3.60	3.88	3.85,	2.09 –	
			12.4, 4.6 Hz,						3.65	1.99 (m,	
			1H), 1.81 (t,							6H)	
			J = 12.1 Hz,								
			1H)								
¹³ C NMR (	¹³ C NMR (151 MHz, D ₂ O): δ (ppm)										

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	100.92	54.39	82.31	68.04	73.23	67.14	-	-	-	22.31 or 22.04
Gal	103.44	68.95	75.36	67.14	N/R	67.42	-	-	-	-
Neu5Ac	173.83	99.74	39.67	68.54	51.62	72.62	68.41	71.78	62.45	22.31 or 22.04

Linker	1	2	3
Н	3.43 – 3.35 (m, 2H)	1.90 – 1.84 (m, 2H)	3.98, 3.70
С	47.80	28.10	67.30



## Synthesis of 47

**47** was synthesized using PPST as described in the methods. White solid after lyophilization (10 mg, 67%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2361.

	H1	H2	Н3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.53	4.03	3.90	4.24	3.95	4.22	-	-	-	2.04/2.04
Gal	4.53	3.56	4.08	3.94	3.65	3.73	-	-	-	-
Neu5Ac	-	-	2.76 (dd, J = 12.5, 4.7 Hz),	3.68	3.85	3.70	3.62	3.89	3.86,	2.04/2.04
			1.80 (t, J = 12.1  Hz)						3.65	

¹H NMR (500 MHz, D₂O): δ (ppm)

¹³C NMR (126 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	<b>C8</b>	C9	NHAc
GalNAc	101.34	51.01	79.87	67.59	72.38	67.33	-	-	-	22.26
Gal	104.62	68.96	75.52	67.28	74.71	60.91	-	-	-	-
Neu5Ac	173.90	99.64	39.69	68.02	51.62	72.74	68.38	71.77	62.43	22.00

Linker	1	2	3
Н	3.40	1.86	3.99, 3.71
С	47.78	28.10	67.14



**48** was synthesized using PPST as described in the methods. White solid after lyophilization (15 mg, 67%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{22}S$ , [M-H]⁻: 836.2361, found 836.2362.

	H1	H2	H3	H4	H5	H6	H7	H8	H9		NHAc
GalNAc	4.50	4.02	3.85	4.23	3.71	3.80	-	-	-		2.04 or 2.03
Gal	4.53	3.58	4.10	3.98	3.88	4.16	-	-			-
Neu5Ac	-	-	2.76, 1.80	3.68	3.85	3.73	3.62	3.89	3.86, 3.64		2.04 or 2.03
¹³ C NMR (126 MHz, D ₂ O): δ (ppm)											
	<b>C1</b>	C2	C3	C4	C5	<b>C6</b>	C	7	C8	<b>C9</b>	NHAc
GalNAc	101.4	1 51.	.02 80.20	67.90	74.93	3 61.2	21 -		-	-	22.22, 22.01
Gal	104.3	5 68.	.85 75.35	67.71	72.41	1 67.3	33 -	-		-	-
Neu5Ac	1738	5 99	78 39 59	68.03	51.62	2 72 7	77 68	3 40	71 73	62.47	22 22 22 01

	( = 0 0 1 MTT	$\mathbf{D}(\mathbf{O})$	c	$\langle \rangle$
'H NMK	(300 MHZ.	$D_{2}O_{1}$	0	(ppm)

Linker	1	2	3
Н	3.39	1.86	3.99, 3.70
С	47.78	28.09	66.96



# Synthesis of 49

**49** was synthesized using PPST as described in the methods. White solid after lyophilization (12 mg, 92%). ESI-Q-TOF-HRMS m/z calculated for  $C_{28}H_{46}N_5O_{25}S_2$ , [M-H]⁻: 916.1929, found 916.1927.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GalNAc	4.52 (d, J	4.04	3.90	4.24	3.96	4.24	-	-	-	2.05 or
	= 8.5 Hz)									2.04
Gal	4.56 (d, J	3.57	4.10	3.99	3.90	4.18	-	-	-	-
	= 7.9 Hz)									
Neu5Ac	-	-	$2.76 (\mathrm{dd}, J = 12.5, 4.7)$	3.69	3.85	3.65	3.62	3.89	3.86,	2.05 or
			Hz), 1.81 (t, $J = 12.1$						3.65	2.04
			Hz)							

¹H NMR (800 MHz, D₂O): δ (ppm)

## ¹³C NMR (201 MHz, D₂O): δ (ppm)

	C1	<b>C2</b>	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GalNAc	101.33	51.00	79.70	67.83	72.36	N/R	-	-	-	22.30
Gal	104.31	68.87	75.35	N/R	72.68	N/R	-	-	-	-
Neu5Ac	173.88	99.81	39.62	N/R	51.64	72.26	N/R	71.76	62.48	22.05

Linker	1	2	3
Η	3.40	1.86	3.99, 3.73

С	47.83	28.13	N/R
	. 1		



#### Synthesis of 50

**50** was synthesized using PPST as described in the methods. White solid after lyophilization (11.5 mg, 85%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{30}S$ , [M-H]⁻: 1127.3315, found 1127.331.

1 H NMR (5	500 MHz,	D ₂ O): δ	(ppm)											
	H1		H2	H3		H4	H5	H6	H	7	H8	H9		NHAc
GalNAc	4.48 (d	J = 8	.5 4.03	3.88		4.18	3.75	3.98	-		-	-		2.04
	Hz)													
Gal	4.54 (d	J = 7	.9 3.57	4.09		4.00	3.80	4.16	-		-	-		-
	Hz)													
Neu5Ac	-		-	2.74,		3.69	3.84	3.72	3.:	58	3.89	3.8	7,	2.04
				1.73								3.6	5	
Neu5Ac'	-		-	2.76,		3.68	3.83	3.72	3.:	58	3.90	3.8	7,	2.04
				1.80								3.6	5	
¹³ C NMR (	126 MHz	z, D ₂ O): δ	(ppm)											
	C1	C2	<b>C3</b>	C4		C5	<b>C6</b>	<b>C7</b>		<b>C8</b>	0	<b>.</b> 9	NHA	2
GalNAc	101.45	51.08	79.42	68.26		73.28	63.74	-		-	-		22.29	or
													22.02	or
													22.01	
Gal	104.25	68.82	75.31	67.16		72.77	67.26	-		-	-		-	
Neu5Ac	173.40	100.38	40.05	68.04	or	51.82	72.57	68.4	1	71.7	4 6	2.63	22.29	or
				67.95									22.02	or
													22.01	
Neu5Ac'	173.83	99.75	39.63	68.04	or	51.62	72.32	68.2	6	71.5	8 6	2.45	22.29	or
				67.95									22.02	or
													22.01	

Linker	1	2	3
Н	3.39	1.86	3.98, 3.71
С	47.77	28.14	67.24



## Synthesis of 36

**36** was synthesized using PPST as described in the methods. White solid after lyophilization (32 mg, 73%). ESI-Q-TOF-HRMS m/z calculated for  $C_{34}H_{56}N_5O_{23}$ , [M-H]⁻: 902.3372, found 902.3376.

¹H NMR (600 MHz, D₂O): δ (ppm)

,	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.51	2.89	3.83	3.92	3.56	3.98,	-	-	-	2.03 –
						386				1.98 (m,
										6H)
Gal	4.51	3.51 (dd,	4.07 (dd, <i>J</i>	3.91	N/R	3.67	-	-	-	-
		J = 9.8,	= 9.8, 3.2			(2H)				
		7.8 Hz,	Hz, 1H)							
		1H)								
Fuc	5.09 (d,	3.67	3.90	3.76 (d,	4.80	1.15 (d,	-	-	-	-
	J = 4.0			J = 3.3		J = 6.6				
	Hz, 1H)			Hz, 1H)		Hz, 3H)				
Neu5Ac	-	-	2.75 (dd, <i>J</i>	3.66	3.81	N/R	N/R	3.87	3.84,	2.03 –
			= 12.6, 4.6						3.62	1.98 (m,
			Hz, 1H),							6H)
			1.78							

## ¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	100.98	55.80	N/R	N/R	N/R	59.62	-	-	-	22.21 or 22.02
Gal	101.59	N/R	75.62	N/R	N/R	61.48	-	-	-	-
Fuc	98.60	N/R	N/R	71.85	66.67	15.26	-	-	-	-
Neu5Ac	173.88	99.64	39.76	N/R	51.67	N/R	N/R	N/R	62.57	22.21 or 22.02

Linker	1	2	3					
Н	3.40 – 3.30 (m, 2H)	1.82 (2H)	3.95, 3.67					
С	47.74	28.10	67.18					
N/D. mat was antad								

N/R: not reported.



# Synthesis of 37

**37** was synthesized using PPST as described in the methods. White solid after lyophilization (37 mg, yield 50%). ESI-Q-TOF-HRMS m/z calculated for  $C_{34}H_{56}N_5O_{23}$ , [M-H]⁻: 902.3372, found 902.3369.

		- /								
	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.57 –	3.89	4.08	3.73	3.55	3.98,	-	-	-	2.06 (s,
	4.52					3.86				3H) or
	(m, 2H)									2.04 (s,
										3H)
Gal	4.57 –	3.52	4.06	3.92	N/R	3.70	-	-	-	-
	4.52					(2H)				
	(m, 2H)									
Fuc	5.01 (d,	3.80	3.88	N/R	4.88 (q,	1.18 (d,	-	-	-	-
	J = 4.0				J = 6.9	J = 6.6				
	Hz,				Hz.	Hz, 2H)				

¹H NMR (600 MHz, D₂O): δ (ppm)

	1H)					0H)							
Neu5Ac	-	-	2.78 (0	dd, J =	3.68	3.85	N/R	Ł	N/R	N/R	3.82,	2.06	(s,
			12.4, 4	4.6 Hz,							3.67	3H)	or
			1H), 1.	78 (t, J								2.04	(s,
			= 12.	2 Hz,								3H)	
			1H)										
¹³ C NMR (151 MHz, D ₂ O): δ (ppm)													
	C1	<b>C2</b>	C3	C4	C5	C6	C7	<b>C8</b>	<b>C9</b>	NF	IAc		
GlcNAc	100.96	55.70	76.03	72.32	75.44	59.69	-	-	-	22.	39 or 22	2.02	
Gal	102.78	68.76	75.59	66.82	N/R	61.64	-	-	-	-			
Fuc	98.04	68.40	N/R	71.84	66.82	15.31	-	-	-	-			
Neu5Ac	173.92	99.36	39.99	69.08	51.65	N/R	N/R	N/R	62.2	8 22.	39 or 22	2.02	

Linker	1	2	3
Η	3.39 (td, J = 6.5, 4.0 Hz, 2H)	1.90 – 1.81 (m, 2H)	3.97, 3.68
С	47.76	28.10	67.17



# Synthesis of 51

**51** was synthesized using PPST as described in the methods. White solid after lyophilization (11 mg, yield 79%). ESI-Q-TOF-HRMS m/z calculated for  $C_{34}H_{56}N_5O_{26}S$ , [M-H]⁻: 982.294, found 982.2937.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	
GlcNAc	4.57 (d,	3.91	3.87	4.02 (t,	3.81	4.43 –	-	-	-	2.07 –	
	J = 8.0			J = 9.2		4.33 (m,				2.01 (m,	
	Hz, 1H)			Hz,		2H)				6H)	
				1H)							
Gal	4.62 (d,	3.51 (dd,	4.10 (dd, J	3.96	N/R	3.69	-	-	-	-	
	J = 7.9	J = 9.9,	= 9.9, 3.2			(2H)					
	Hz, 1H)	7.8 Hz,	Hz, 1H)								
		1H)									
Fuc	5.11 (d,	3.67	N/R	3.77	4.81	1.17 (d,	-	-	-	-	
	J = 4.0					J = 6.6					
	Hz, 1H)					Hz, 3H)					
Neu5Ac	-	-	2.75 (dd, J	3.69	3.86	N/R	N/R	3.91	3.90,	2.07 –	
			= 12.4, 4.7						3.66	2.01 (m,	
			Hz, 1H),							6H)	
			1.80								
¹³ C NMR (	¹³ C NMR (126 MHz, D ₂ O); δ (ppm)										
	C1	$C_{1}$				7 09	CO	NI	IAa		

^I H NMR	(500 MHz,	$D_2O)$	: δ (p	opm)
--------------------	-----------	---------	--------	------

	C1	C2	<b>C3</b>	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	100.96	55.68	74.69	72.86	N/R	65.87	-	-	-	22.21 or 22.04
Gal	101.16	69.39	75.39	N/R	N/R	61.47	-	-	-	-
Fuc	98.55			N/R	66.70	15.28	-	-	-	-

Neu5Ac	174.05	99.56	39.70	N/R	51.73	N/R	N/R	71.34	62.52	22.21 or 22.04
--------	--------	-------	-------	-----	-------	-----	-----	-------	-------	----------------

Linker	1	2	3
Н	3.43 – 3.32 (m, 2H)	184 (2H)	3.96, 3.68
С	47.77	28.10	67.26



## Synthesis of 52

**52** was synthesized using PPST as described in the methods. White solid after lyophilization (15 mg, yield 54%). ESI-Q-TOF-HRMS m/z calculated for  $C_{34}H_{56}N_5O_{26}S$ , [M-H]⁻: 982.294, found 982.2943.

¹H NMR (600 MHz, D₂O): δ (ppm)

Ì	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.54	3.90	3.88	3.96	3.61	4.04 (dd, J	-	-	-	2.05 -
						= 12.2, 2.3				2.02 (m,
						Hz, 1H),				6H)
						3.90				
Gal	4.55	3.55 (dd,	4.12	3.99	N/R	4.13 (2H)	-	-	-	-
		J = 9.8,								
		7.9 Hz,								
		1H)								
Fuc	5.11 (d,	3.65	3.91	3.81	4.82	1.18 (d, J =	-	-	-	-
	J = 4.0					6.7 Hz,				
	Hz, 1H)					3H)				
Neu5Ac	-	-	2.78 (dd, J	3.70	3.87	N/R	N/R	N/R	3.89,	2.05 –
			= 12.4, 4.6						3.65	2.02 (m,
			Hz, 1H),							6H)
			1.81							

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	C9	NHAc
GlcNAc	101.66	56.52	75.74	74.46	76.01	60.45	-	-	-	22.91 or 22.71
Gal	102.22	69.84	76.13	N/R	N/R	N/R	-	-	-	-
Fuc	99.24	N/R	N/R	73.62	67.35	16.00	-	-	-	-
Neu5Ac	174.45	100.44	40.42	N/R	52.35	N/R	N/R	N/R	63.29	22.91 or 22.71

Linker	1	2	3
Н	3.43 – 3.34 (m, 2H)	1.85	3.97, 3.69
С	48.44	28.79	
	4 1		

N/R: not reported.



**53** was synthesized using PPST as described in the methods. White solid after lyophilization (7.7mg, 55%).

ESI-Q-TOF-HRMS m/z calculated fo	$C_{34}H_{56}N_5O_{29}S_{29}$	, [M-H] ⁻ : 1062.2508,	found 1062.2508
----------------------------------	-------------------------------	-----------------------------------	-----------------

$-\Pi$ INME (OUU MITZ, D ₂ U), O (DDII	¹ H NMR	(600 MHz.	D ₂ O): 8	S (ppm
---------------------------------------------------	--------------------	-----------	----------------------	--------

	H1	H2	Н3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.55 (d,	3.88	3.86	4.00	3.82	4.37	-	-	-	2.02 –
	J = 8.0									1.99 (m,
	Hz, 1H)									6H)
Gal	4.60 (d,	3.51 (dd,	4.11	4.00	3.81	4.11	-	-	-	-
	J = 7.8	J = 9.9,								
	Hz, 1H)	7.9 Hz,								
		1H)								
Fuc	5.08 (d,	3.63	3.89	3.70	4.71	1.15 (d,	-	-	-	-
	J = 4.0					J = 6.7				
	Hz, 1H)					Hz, 3H)				
Neu5Ac	-	-	2.74 (dd, J	3.67	3.85	3.76	3.58	3.89	3.87,	2.02 –
			= 12.4, 4.6						3.63	1.99 (m,
			Hz, 1H),							6H)
			1.80							

¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	C3	C4	C5	C6	C7	<b>C8</b>	C9	NHAc
GlcNAc	100.94	55.67	74.92	73.31	72.99	66.00	-	-	-	22.20
Gal	101.26	69.29	75.14	66.85	72.02	67.03	-	-	-	-
Fuc	98.60	69.07	67.88	71.99	66.68	15.32	-	-	-	-
Neu5Ac	173.53	99.41	39.57	68.06	51.67	72.90	68.29	71.16	62.61	22.03

Linker	1	2	3
Н	3.39 – 3.30 (m, 2H)	1.82	3.94, 3.65
С	47.75	28.09	67.20



# Synthesis of 54

**54** was synthesized using PPST as described in the methods. White solid after lyophilization (13 mg, yield 62%). ESI-Q-TOF-HRMS m/z calculated for  $C_{34}H_{56}N_5O_{26}S$ , [M-H]⁻: 982.2940, found 982.2939.

¹H NMR (600 MHz, D₂O): δ (ppm)

Ì	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
GlcNAc	4.52	3.91	4.08	3.70	N/R	3.98,	-	-	-	2.06 (s,
	(d, J =					3.86				3H) or
	8.6									2.04 (s,

	Ц7									2U)	
	112,									511)	
-	<u>IH)</u>										
Gal	4.57	3.52	4.07	3.96	N/R	4.17 (dd,	-	-	-	-	
	(d, J =	(dd, J =				J = 10.6,					
	7.7	9.8, 7.8				4.2 Hz,					
	Hz,	Hz, 1H)				1H), 4.10					
	1H)										
Fuc	5.00	3.76	N/R	N/R	4.89	$1.18 (\mathrm{d}, J)$	-	-	-	-	
	(d, J =				(q, J =	= 6.6 Hz,					
	4.0				6.8	3H)					
	Hz,				Hz,						
	1H)				1H)						
Neu5Ac	-	-	2.78 (dd, $J$	3.69	3.85	N/R	N/R	N/R	3.85,	2.06	(s,
			= 12.4, 4.6						3.66	3H)	or
			Hz, 1H),							2.04	(s,
			1.78 (t, $J =$							3H)	
			12.2 Hz,								
			1H)								

¹³C <u>NMR (151 MHz, D₂O): δ (ppm)</u>

	C1	C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	101.04	55.59	76.24	72.54	N/R	59.64	-	-	-	22.40 or 22.03
Gal	102.58	68.67	N/R	66.71	N/R	67.77	-	-	-	-
Fuc	98.12	68.41	N/R	N/R	66.78	15.36	-	-	-	-
Neu5Ac	173.81	99.48	39.92	N/R	51.63	N/R	N/R	N/R	62.31	22.40 or 22.03

Linker	1	2	3
Н	3.44 – 3.34 (m, 2H)	1.88 – 1.81 (m, 2H)	3.97, 3.68
С	47.77	28.10	67.19



# Synthesis of 55

**55** was synthesized as described in the methods. White solid after lyophilization (2.4 mg, 87%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{27}$ , [M-H]⁻: 1047.3747, found 1047.3747.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	•
GlcNAc	4.53	3.73	N/R	3.75	N/R	4.02,	-	-	-	2.10	_
						3.88				2.02	(m,
										9H)	
Gal	4,56	3.57	4.10 (dd, $J = 10.0$ ,	3.98	N/R	3.75	-	-	-	-	
			3.1 Hz, 1H)			(2H)					
Neu5Ac	-	-	2.69  (dd, J = 12.3,	3.62	3.84	N/R	N/R	4.15	4.22,	2.10	_
			4.4 Hz, 1H), 1.75 (t,						3.77	2.02	(m,
			<i>J</i> = 12.1 Hz, 1H)							9H)	
Neu5Ac'	-	-	2.79 (dd, $J = 12.5$ ,	3.68	3.84	N/R	N/R	3.92	3.89,	2.10	_

¹H NMR (600 MHz, D₂O): δ (ppm)

			4.6 Hz, <i>J</i> = 12.1	1H), 1.7 Hz, 1H)	75 (t,					366	2.02 (m, 9H)
¹³ C NMR (	151 MH	z, D ₂ 0	D): δ (ppr	n)						·	
	C1		C2	C3	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
GlcNAc	101.16		55.14	N/R	78.04	N/R	59.98	-	-	-	22.32 or 22.17
											or 22.04
Gal	102.55		69.31	75.46	N/R	N/R	61.10	-	-	-	-
Neu5Ac	173.51	or	100.22	39.66	N/R	52.28	N/R	N/R	78.19	61.56	22.32 or 22.17
	173.36										or 22.04
Neu5Ac'	173.51	or	100.51	40.49	N/R	51.75	N/R	N/R	71.75	62.57	22.32 or 22.17
	173.36										or 22.04

<b>H</b> $344 = 334$ (m 2H) $189 = 181$ (m 2H) $399$	
11   5.44   5.54   (11, 211)   1.05   1.01   (11, 211)   5.57	3.68
C 47.78 28.10 67.13	



# Synthesis of 56

**56** was synthesized as described in the methods. White solid after lyophilization (2.6 mg, 93%). ESI-Q-TOF-HRMS m/z calculated for  $C_{37}H_{60}N_5O_{27}$ , [M-H]⁻: 1006.3481, found 1006.3485.

¹H NMR (600 MHz, D₂O): δ (ppm)

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc
Glc	4.50	3.35 -	3.65	3.69	3.61	4.01,	-	-	-	-
	(d, J =	3.30				3.86				
	8.0 Hz,	(m,								
	1H)	1H)								
Gal	4.53	3.58	4.10 (dd, J	3.97	3.73	3.75	-	-	-	-
	(d, J =		= 9.9, 3.2							
	7.8 Hz,		Hz, 1H)							
	1H)									
Neu5Ac	-	-	2.69 (dd, J	3.62	3.83	N/R	N/R	4.16 -	4.19 (dd,	2.08 (s,
			= 12.5, 4.5					4.13	J = 12.3,	3H) or
			Hz, 1H),					(m,	3.6 Hz,	2.04 (s,
			1.79 - 1.72					1H)	1H), 3.77	3H)
			(m, 2H)							
Neu5Ac'	-	-	2.79 (dd, J	3.68	3.83	3.68	3.61	3.91	3.89,	2.08 (s,
			= 12.4, 4.7						3.65	3H) or
			Hz, 1H),							2.04 (s,
			1.79 - 1.72							3H)
			(m, 2H)							

## ¹³C NMR (151 MHz, D₂O): δ (ppm)

	C1	C2	<b>C3</b>	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc
Glc	102.01	72.71	74.15	77.90	74.68	59.86	-	-	-	-
Gal	102.54	69.15	75.32	67.22	75.08	60.96	-	-	-	-

Neu5Ac	173.37	or	100.06	39.56	67.80	52.14	N/R	N/R	78.08	61.43	22.18	or
	173.22										21.90	
Neu5Ac'	173.37	or	100.38	40.36	67.80	51.61	72.52	68.36	71.61	62.43	22.18	or
	173.22										21.90	

Linker	1	2	3
Η	3.50 – 3.44 (m, 2H)	1.92 (p, J = 7.2 Hz, 2H)	4.01, 3.78
С	47.75	28.10	67.33



# Synthesis of 57

**57** was synthesized as described in the methods. White solid after lyophilization (2 mg, 72%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{27}$ , [M-H]⁻: 1047.3747, found 1047.3749.

	H1	H2	H3		H4	H5	H6	H7	H8	H9		NHA	c
GlcNAc	4.56 (d,	3.82	3.79		3.54	3.49	3.93,	-	-	-		2.10	-
	J = 8.2						3.76					2.01	(m,
	Hz,											9H)	
	1H)												
Gal	4.49 (d,	3.53	4.09	(dd, J =	3.95	3.72	3.73	-	-	-		-	
	J = 7.8		9.9,	3.1 Hz,									
	Hz,		1H)										
	1H)												
Neu5Ac	-	-	2.69	(dd, J =	3.59	3.82	N/R	N/R	4.17 -	4.20 (	$\mathrm{dd}, J$	2.10	_
			12.3,	4.4 Hz,					4.12	= 12.1	, 3.8	2.01	(m,
			1H),	1.77 –					(m,	Hz,	1H),	9H)	
			1.69	(m, 1H)					1H)	3.94			
Neu5Ac'	-	-	2.77	(dd, J =	3.67	3.82	N/R	N/R	3.91	3.88, 1	3.66	2.10	_
			12.4,	4.6 Hz,								2.01	(m,
			1H),	1.77 –								9H)	
			1.69	(m, 1H)									
$^{13}C$ NMR (	126 MHz,	$D_2O)$	: δ (ppr	n)									
	C1		C <b>2</b>	<b>C3</b>	C4	C5	<b>C6</b>	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHA	Ac	
GlcNAc	100.96	4	54.39	82.74	68.46	75.37	60.74	-	-	-	22.3	7 or 22	2.31
											or 22	2.04	
Gal	103.60	(	58.78	75.38	67.61	75.06	60.05	-	-	-	-		
Neu5Ac	173.38	or	99.93	39.83	N/R	52.24	N/R	N/R	78.57	61.61	22.3	7 or 22	2.31
	173.63										or 22	2.04	
Neu5Ac'	173.38	or	100.46	41.52	N/R	51.77	N/R	N/R	71.73	62.58	22.3	7 or 22	2.31
	173.63										or 22	2.04	

¹ H NMR (500 MHz, D ₂ O); δ (ppm)	$^{1}\mathrm{H}$	NMR	(500	MHz.	$D_2O^{2}$	): δ (	(ppm)	
---------------------------------------------------------	------------------	-----	------	------	------------	--------	-------	--

Linker	1	2	3
Н	3.95 – 3.86 (m, 2H)	2.42 – 2.34 (m, 2H)	4.52, 4.21
С	47.79	28.11	67.18



#### Synthesis of 58

**58** was synthesized as described in the methods. White solid after lyophilization (19.2 mg, 92%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{27}$ , [M-H]⁻: 1047.3747, found 1047.3750.

	H1	H2	H3			H4	H5	H6		H7	H8	H9	NHAc			
GalNAc	4.51	4.02	3.88			4.17	3.70	3.79	or	-	-	-	2.07 or	2.06		
								3.72					or 2.04			
Gal	4.52	3.55	4.07			3.93	3.63	3.79	or	-	-	-	-			
										3.72						
Neu5Ac	-	-	2.70 (	dd, J = 12.3, 3		3, 3.61 3.8		N/R		N/R	4.15	4.20	2.07 or	2.06		
-			4.4 Hz	z), 1.73									or 2.04			
Neu5Ac'	-	-	2.79 (	$\mathrm{dd}, J = 1$	12.3,	3.69	3.82	3.70		3.61	3.90	3.89,	2.07 or	2.06		
			4.7 Hz	z), 1.73								3.66	or 2.04			
¹³ C NMR (	³ C NMR (126 MHz, D ₂ O): δ (ppm)															
	C1		C2	C3	C4		C5	<b>C6</b>	C	7	<b>C8</b>	С9	NHAc			
GalNAc	101.4	.5	51.09	80.13	67.8	7	74.76	60.94	-		-	-	22.35 or			
													22.30	or		
													22.02			
Gal	104.7	7	68.95	75.29	67.2	0	74.73	61.03	-		-	-	-			
Neu5Ac	173.5	9	99.93	39.78	68.1	0	51.74	N/R	N	/R	78.48	61.59	22.35 or			
	or				or								22.30	or		
	173.3	4			67.9	0							22.02			
Neu5Ac'	173.5	9	100.45	40.50	68.1	0	52.21	72.64	68	3.43	71.70	62.55	22.35 or			
	or				or								22.30	or		
	173.3	4			67.9	0							22.02			

¹H NMR (500 MHz, D₂O): δ (ppm)

Linker	1	2	3
Н	3.40	1.86	3.98, 3.72
С	47.78	28.10	67.01

N/R: not reported.



## Synthesis of 59

**59** was synthesized as described in the methods. White solid after lyophilization (2.2 mg, 80%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{30}S$ , [M-H]⁻: 1127.3315, found 1127.3315.

 $^1\text{H}$  NMR (600 MHz, D2O):  $\delta$  (ppm)

	H1	H2	H3		H4	H5	H	6		H7	H8	H9	NHAc
GlcNAc	4.56 (d,	3.77	7 N/R		3.81	N/R	4.4	47 (dd,	J =	-	-	-	2.12 –
	J = 7.9						11	.1, 2.0	Hz,				1.99 (m,
	Hz, 1H)						1H	I), 4.29	$(\mathrm{dd}, J)$				9H)
							=	11.4, 5.	1 Hz,				
							1H	I)					
Gal	4.62 (d,	3.57	7 4.11		4.02	N/R	3.′	76 (2H)		-	-	-	-
	J = 7.8												
	Hz, 1H)												
Neu5Ac	-	-	2.70	_	3.66	3.84	N/	'R		N/R	4.16	4.14,	2.12 –
			2.62	(m,								3.76	1.99 (m,
			1H),	1.81									9H)
Neu5Ac'	-	-	2.78	$(\mathrm{dd}, J)$	3.68	3.84	N/	'R		N/R	3.92	3.91,	2.12 –
			= 12	6, 4.6								3.66	1.99 (m,
			Hz,	1H),									9H)
			1.75										
¹³ C NMR (	150 MHz,	$D_2O$	): δ (ppr	n)									
	C1		C2	C3	C4	C5		C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NH	Ac
GlcNAc	191.13		55.03	N/R	77.32	2 N/I	R	66.63	-	-	-	22.3	0 or 22.17
												or 2	2.04
Gal	101.96		68.21	75.22	67.77	7 N/I	R	61.07	-	-	-	-	
Neu5Ac	173.68	or	100.38	39.02	N/R	52.	23	N/R	N/R	78.08	61.7	/5 22.3	0 or 22.17
	173.45											or 2	2.04
Neu5Ac'	173.68	or	100.68	40.48	N/R	51.	73	N/R	N/R	71.72	62.5	7 22.3	0 or 22.17
	173.45											or 2	2.04

Linker	1	2	3
Н	3.39 (td, J = 6.7, 3.2 Hz, 2H)	1.86 (2H)	3.99, 3.68
С	47.79	28.10	67.26



# Synthesis of 60

**60** was synthesized as described in the methods. White solid after lyophilization (2.3 mg, 85%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{30}S$ , [M-H]⁻: 1127.3315, found 1127.3312.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	
GlcNAc	4.51 (d, J	3.72	4.10	3.71		3.97,	-	-	-	2.07	_
	= 7.6 Hz,					3.84				2.00	(m,
	1H)									9H)	
Gal	4.57 (d, J	3.55	4.10  (dd,  J =	4.00	3.95	4.17	-	-	-	-	
	= 7.9 Hz,		9.9, 3.2 Hz,								
	1H)		1H)								
Neu5Ac	-	-	2.66  (dd, J =	3.59	3.81	N/R	N/R	4.13	4.15,	2.07	_
			12.3, 4.4 Hz,						3.73	2.00	(m,

#### ¹H NMR (600 MHz, D₂O): δ (ppm)

			1H),	1.73							9H)	
Neu5Ac'	-	-	2.76	(dd, J)	= 3.65	3.81	N/R	N/R	3.89	3.83,	2.07	_
			12.4,	4.6 Hz	z,					3.62	2.00	(m,
			1H),	1.73							9H)	
³ C NMR (151 MHz, D ₂ O): δ (ppm)												
	C1	C2	<b>C3</b>	C4	C5	<b>C6</b>	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc		
GlcNAc	101.15	55.19	N/R	78.88	N/R	60.20	-	-	-	22.33	or 22.1	9 or
										22.05		
Gal	102.36	67.47	75.24	N/R	N/R	N/R	-	-	-	-		
Neu5Ac	173.41	100.35	39.61	N/R	52.24	N/R	N/R	78.19	61.60	22.33	or 22.1	9 or
										22.05		
Neu5Ac'	173.41	100.44	40.48	N/R	51.74	N/R	N/R	71.75	62.55	22.33	or 22.1	9 or
										22.05		

Linker	1	2	3
Η	3.41 – 3.31 (m, 2H)	1.83 (p, J = 6.4 Hz, 2H)	3.96, 3.66
С	47.77	28.10	67.12



# Synthesis of 61

**61** was synthesized as described in the methods. White solid after lyophilization (2.1 mg, 78%). ESI-Q-TOF-HRMS m/z calculated for  $C_{37}H_{60}N_5O_{30}S$ , [M-H]⁻: 1086.3049, found 1086.3049.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHA	c
Glc	4.51	3.34	3.67	3.75	3.83	$4.45 (\mathrm{dd}, J=$	-	-	-	-	
	(d, J =	(dd, J =				11.2, 2.0					
	8.0	9.4, 8.0				Hz, 1H),					
	Hz,	Hz,				$4.26 (\mathrm{dd}, J=$					
	1H)	1H)				11.2, 5.2					
						Hz, 1H)					
Gal	4.59	3.56	4.10	4.01	3.73	3.75	-	-	-	-	
	(d, J =										
	7.9										
	Hz,										
	1H)										
Neu5Ac	-	-	2.64 (dd, J	3.64	3.82	N/R	N/R	3.91	4.14,	2.07	(s,
			= 12.4, 4.5						3.75	3H)	or
			Hz, 1H),							2.03	(s,
			1.80 (t, $J =$							3H)	
			12.3 Hz,								
			1H)								
Neu5Ac'	-	-	2.77 (dd, J	3.66	3.82	3.64	3.61	4.15	3.89,	2.07	(s,
			= 12.3, 4.8						3.65	3H)	or
			Hz, 1H),							2.03	(s,

¹H NMR (500 MHz, D₂O): δ (ppm)

1.74 (t, J = 1)			3H)
12.2 Hz,			
1H)			

¹³C NMR (126 MHz, D₂O): δ (ppm)

<u> </u>	<b>120 11112, 2, 2, 2, 2, 2, 3</b>	<u>, , , , , , , , , , , , , , , , , , , </u>	/								
	C1	C2	<b>C3</b>	C4	C5	C6	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc	
Glc	101.87	72.54	74.05	77.03	72.39	66.45	-	-	-	-	
Gal	102.00	69.38	75.07	67.61	74.82	60.93	-	-	-	-	
Neu5Ac	173.54 or	100.19	38.84	68.06	52.08	N/R	N/R	78.00	61.60	22.14	or
	173.32									21.88	
Neu5Ac'	173.54 or	100.55	40.34	68.06	51.58	72.44	68.39	71.55	62.41	22.14	or
	173.32									21.88	

Linker	1	2	3
Н	3.46 (t,	1.92 (p,	3.98,
	J = 6.7	J = 6.5	3.78
	Hz,	Hz,	
	2H)	2H)	
С	47.73	28.10	67.37



# Synthesis of 62

**62** was synthesized as described in the methods. White solid after lyophilization (2.2 mg, 81%). ESI-Q-TOF-HRMS m/z calculated for  $C_{37}H_{60}N_5O_{30}S$ , [M-H]⁻: 1086.3049, found 1086.3049.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHAc	
Glc	4.50 (d,	3.37 –	3.66	3.66	3.62	4.01,	-	-	-	-	
	J = 8.0	3.30				3.94					
	Hz, 1H)	(m,									
		1H)									
Gal	4.56 (d,	3.58	4.12	4.03	3.98	4.20	-	-	-	-	
	J = 8.0					(2H)					
	Hz, 1H)										
Neu5Ac	-	-	2.68 (dd, $J =$	3.62	3.83	N/R	N/R	4.15	4.17,	2.08	(s,
			12.3, 4.4 Hz,						3.84	3H)	or
			1H), 1.79 –							2.04	(s,
			1.71 (m, 1H)							3H)	
Neu5Ac'	-	-	2.78  (dd,  J =	3.66	3.83	3.66	N/R	3.91	3.89,	2.08	(s,
			12.3, 4.6 Hz,						3.65	3H)	or
			1H), 1.79 –							2.04	(s,
			1.71 (m, 1H)							3H)	
13C NIMP (	126 MHz	$\overline{D}$ $\overline{O} \cdot \hat{s}$ (r				•					

$^{+}H$ INIVIK (SUU IVIHZ, D $_{2}$ U); 0 (DDM)	¹ H NMR (	(500 MHz.	$D_2O$ ):	δ (ppm)
-------------------------------------------------	----------------------	-----------	-----------	---------

C INNIK (	120 101112	$, D_2 O_{2} O_{2$	0 $10000000000000000000000000000000000$										
	C1	C2	<b>C3</b>	C4	C5	<b>C6</b>	<b>C7</b>	<b>C8</b>	<b>C9</b>	NHAc			
Glc	101.9	72.65	74.13	79.18	74.57	60.10	-	-	-	-			
Gal	102.67	69.01	75.09	67.20	72.65	67.42	-	-	-	-			

Neu5Ac	173.29	100.23	39.47	67.84	52.14	N/R	N/R	78.04	61.48	22.19 or 21.91
Neu5Ac'	173.29	100.32	40.36	68.02	51.61	72.50	N/R	71.61	62.43	22.19 or 21.91

Linker	1	2	3
Н	3.47 (t, J = 6.7 Hz, 2H)	1.92 (p, J = 6.5 Hz, 2H)	3.99, 3.77
С	47.75	28.10	67.20



# Synthesis of 63

**63** was synthesized as described in the methods. White solid after lyophilization (2 mg, 74%). ESI-Q-TOF-HRMS m/z calculated for  $C_{37}H_{60}N_5O_{33}S_2$ , [M-H]⁻: 1166.2617, found 1166.2614.

¹H NMR (500 MHz, D₂O): δ (ppm)

	H1	H2	H3		H4	H5	H	6		H7	H	3	H9		NHA	c
Glc	4.51	3.39 -	- 3.69		3.68	3.85	4.4	47 (dd, .	J = [	-	-		-		-	
	(d, J =	3.32					11	.2, 2.0 I	Hz,							
	8.0	(m,					1H	I), 4	.24							
	Hz,	1H)					(d	d, J = 11	.3,							
	1H)						5.9	9 Hz, 2F								
Gal	4.59	3.57	4.12		4.05	4.00	4.2	20 (2H)		-	-		-		-	
	(d, J =															
	7.9															
	Hz,															
	1H)															
Neu5Ac	-	-	2.65	$(\mathrm{dd}, J)$	3.64	3.82	N/	R		N/R	4.1	5	4.14	,	2.07	(s,
			= 12.	3, 4.5									3.77		3H)	or
			Hz,	1H),											2.03	(s,
			1.75 (	t, $J =$											2H)	
			12.1	Hz,												
			1H)									_				
Neu5Ac'	-	-	2.77	$(\mathrm{dd}, J)$	3.66	3.82	3.6	51		3.58	3.9	1	3.89	,	2.07	(s,
			= 12.4	4, 4.6									3.65		3H)	or
			Hz,	1H),											2.03	(s,
			1.75 (	t, $J = $											2H)	
			12.1	HZ,												
	126 1411		(1H)													
¹³ C NMR (	126 MHZ	$, D_2 O)$ :	o (ppm)	<u>C2</u>	CA	CE	,	<u>C(</u>	07	C	0	C		NI	TTA -	
	UI 101.07		<u>C2</u>		C4 70.0		$\frac{1}{2}$	<u>Co</u>	<u>U</u>		5	C	9	IN	нас	
GIC	101.8/		/2.44	/4.0/	/8.8	$\frac{4}{7}$	.30	66./4	-	-		-		-		
Gal	102.30		69.16	/4.82	6/.3	/ /2.	.48	6/.46	-	-		-	(5	-	1.7	
Neu5Ac	1/3.43	or	100.18	38.83	N/K	52.	.05	N/K	N/R	( <i>  //</i>	.98	61	.65	24	2.15	or
	1/3.32		100 (2	40.25		- 1	50	70.44		71	50	()	41	2	1.89	
Neu5Ac'	1/3.43	or	100.63	40.35	N/R	51.	.38	12.44	N/R	(   / I	.36	62	.41	22	2.15	or
	1/3.32													2	1.89	

Linker	1	2	3
			1

Н	3.46 (t, J = 6.8  Hz, 2H)	1.92 (p, J = 6.5 Hz, 2H)	3.98, 3.78
С	47.74	28.10	67.42



#### Synthesis of 64

¹H NMR (600 MHz, D₂O): δ (ppm)

**64** was synthesized as described in the methods. White solid after lyophilization (12 mg, 89%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{30}S$ , [M-H]⁻: 1127.3315, found 1127.3317.

	H1	H2	H3			H4	H5	H6	H7	H8	H	9	NHAc	
GalNAc	4.53	4.03	3.90			4.23	3.94	4.20	-	-	-		2.08 or	2.06
													or 2.04	
Gal	4.52	3.55	4.08	4.08			3.66		-	-	-		-	
Neu5Ac	-	-	2.69 (d	d, $J =$	12.4,	3.60	3.83	N/R	N/R	4.16	4.	20	2.08 or	2.06
			4.6 Hz,	1H), 1.	73								or 2.04	
Neu5Ac'	-	-	2.79 (d	d, $J =$	d, J = 12.3,		3.83	N/R	3.62	3.90	3.	.89,	2.08 or	2.06
			4.4 Hz,	1H), 1.	73						3.	.67	or 2.04	
¹³ C NMR (201 MHz, D ₂ O): δ (ppm)														
	C1		C2	<b>C3</b>	C4		C5	C6	<b>C7</b>	<b>C8</b>		<b>C9</b>	NHAc	
GalNAc	101.4	-1	51.00	79.95	67.6	8	72.42	67.34	-	-		-	22.34	or
													22.29	or
													22.01	
Gal	104.8	4	68.95	75.30	67.22	2	74.72	60.99	-	-		-	-	
Neu5Ac	173.6	1 or	99.95	39.76	68.10	0 or	51.74	N/R	N/R	78.4	49	61.59	22.34	or
	173.3	5			67.94	4							22.29	or
													22.01	
Neu5Ac'	173.6	1,	100.42	40.50	68.10	0 or	52.22	72.63	68.45	5   71.0	69	62.54	22.34	or
	173.3	5			67.94	4							22.29	or
													22.01	

Linker	1	2	3
Н	3.40	1.86	4.00, 3.72
С	47.80	28.12	67.17

N/R: not reported.



## Synthesis of 65

**65** was synthesized as described in the methods. White solid after lyophilization (11.2 mg, 83%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{30}S$ , [M-H]⁻: 1127.3315, found 1127.3316.

1111111(0	001011	$\underline{,}_{2}$	<u>, , , , , , , , , , , , , , , , , , , </u>											
	H1	H2	H3	H	4	H5	H6	H7	H8	H	9	NHA	c	
GalNAc	4.51	4.04	3.85	4.	23	3.72	3.74	-	-	-		2.07 c	or 2.06 or	2.04
Gal	4.54	3.57	4.10	3.	99	3.90	4.19	-	-	-		-		
Neu5Ac	-	-	2.69, 1.	74 3.	62	3.83	N/R	N/R	4.17	N/	′R	2.07 c	or 2.06 or	2.04
Neu5Ac'	-	-	2.78, 1.	74 3.	69	3.83	3.70	3.66	3.91	3.9	90, 3.66	2.07 c	or 2.06 or	2.04
¹³ C NMR (201 MHz, D ₂ O): δ (ppm)														
	C1		C2	<b>C3</b>	0	24	C5	C6	C	7	<b>C8</b>	С9	NHAc	
GalNAc	101.4	.9	50.98	80.32	2 6	7.81	74.94	61.2	4 -		-	-	22.31	or
													22.29	or
													22.01	
Gal	104.5	3	68.82	75.18	6	7.22	72.44	67.9	3 -		-	-	-	
Neu5Ac	173.4	9 or	100.05	39.72	6	8.11,	51.73	N/R	N/	R	78.42	61.59	22.31	or
	173.3	6			6	7.93							22.29	or
													22.01	
Neu5Ac'	173.4	9 or	100.38	40.48	6	8.11,	52.22	72.6	1 68	.47	71.68	62.52	22.31	or
	173.3	6			6	7.93							22.29	or
													22 01	

¹H NMR (600 MHz, D₂O): δ (ppm)

Linker	1	2	3
Η	3.39	1.87	4.00, 3.72
С	47.78	28.10	66.98



## Synthesis of 66

**66** was synthesized as described in the methods. White solid after lyophilization (20 mg, 77%). ESI-Q-TOF-HRMS m/z calculated for  $C_{39}H_{63}N_6O_{33}S_2$ , [M-H]⁻: 1207.2883, found 1207.2885.

	H1	H2	H3	H4	H5	H6	H7	H8	H9	NHA	Ac
GalNAc	4.51	4.04	3.90	4.23	3.98	4.22	-	-	-	2.08	or 2.07 or 2.04
Gal	4.54	3.56	4.09	N/R	3.90	4.18	-	-	-	-	
Neu5Ac	-	-	2.69, 1.75	3.62	3.83	N/R	N/R	4.16	4.20, 3.7	1 2.08	or 2.07 or 2.04
Neu5Ac'	-	-	2.78, 1.75	3.68	3.83	N/R	3.61	3.90	3.91, 3.60	5 2.08	or 2.07 or 2.04
¹³ C NMR (201 MHz, D ₂ O): δ (ppm)											
	<b>C1</b>		C2	C3	C4	C5	<b>C6</b>	<b>C7</b>	<b>C8</b>	С9	NHAc
GalNAc	101.3	7	50.96	79.77	67.88	72.36	67.1	8 -	-	-	22.34 or 22.30
											or 22.02
Gal	104.4	8	68.84	75.15	N/R	72.68	67.4	7 -	-	-	-
Neu5Ac	173.5	1 or	100.09	39.69	67.96	51.73	N/R	N/]	R 78.43	61.60	22.34 or 22.30
	173.3	9									or 22.02
Neu5Ac'	173.5	1 or	100.37	40.48	N/R	52.22	72.6	1 N/I	R 71.69	62.53	22.34 or 22.30
	173.3	9									or 22.02

¹H NMR (600 MHz, D₂O): δ (ppm)

Linker	1	2	3
Н	3.40	1.87	4.00, 3.73
С	47.82	28.12	67.13

N/R: not reported.

## 4. Microarray Studies

#### 4.1 General procedure for Hydrogenolysis Mediated reduction of glycan terminal azide group.

Glycan substrate (0.5 mg) was dissolved in 300  $\mu$ L DI water, and palladium hydroxide on carbon slurry (0.3 mg, 20% wt suspended in water solution) was added to the above solution. The reaction was vigorously stirred under an atmosphere of hydrogen and monitored by TLC until no starting material could be detected (2h). Subsequently, the reaction was filtered through a syringe filter (0.2 microns) to remove the catalyst, and the filtrate was lyophilized to give amine-linked glycan products as a white fluffy solid.

#### 4.2 Glycan microarray printing

66 amine-linked glycans were printed using a Scienion sciFLEXARRAYER S1 non-contact microarray printer equipped with a Scienion PDC80 nozzle (Scienion Inc) on the surface of N-hydroxy succinimide (NHS)-activated glass slides (NEXTERION[®] Slide H, Schott Inc) to form glycan microarray. Glycans were dissolved in sodium phosphate buffer (250 mM, pH 8.5) at a concentration of 100 μM and printed in replicates of 4 (spot volume of ~400 pL, at 20 °C and 50% humidity). Each slide contained 14 subarrays (2x7), and 1 subarray displayed 288 spots (18 x16). Slides were incubated overnight in a saturated NaCl chamber (providing a 75% relative humidity environment) after printing and were blocked with 5 mM ethanolamine in Tris-HCl buffer (pH 9, 50 mM) for 1 h at 50 °C and rinsed with DI water.

#### 4.3 Screening of proteins

Sub-arrays were incubated with the protein of interest at the indicated concentrations in TSM binding buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 2 mM MgCl₂, 0.05% Tween, 1% BSA) for 0.5-1h at r.t. followed by washing. Wash steps involved 2 successive washes with TSM wash buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 2 mM MgCl₂, 0.05% Tween-20) - TSM buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 2 mM MgCl₂) - deionized H₂O. All incubation and wash steps were performed at RT.

#### Plant lectins:

Working solutions at specific concentrations of biotinylated plant lectins were freshly prepared by diluting an appropriate amount of stock solution in a TSM binding buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 2 mM MgCl₂, 0.05% Tween, 1% BSA). The above working solution (100  $\mu$ L) was carefully added to the subarray and was allowed to incubate for 1h in the dark, followed by a washing procedure. Then, the subarrays were incubated with 100  $\mu$ L Streptavidin-AlexaFluor® 647 (5  $\mu$ g/mL) in TSM binding buffer for 0.5 h in the dark. After incubation, the slide was performed using a washing procedure and kept in the dark before analysis.

#### Fc-tagged Siglecs:

Streptavidin-AlexaFluor[®] 647 (5  $\mu$ g/mL) was pre-complexed with biotinylated anti-IgG Fc (5  $\mu$ g/mL) in a 1:1 molar ratio in 100  $\mu$ L TMS binding buffer and was incubated on ice for 15 min as the pre-mixed solution for further use. Working solutions of Fc-tagged Siglecs at specific concentrations were freshly

prepared by diluting an appropriate amount of stock solution in a TSM binding buffer. The above working solution (100  $\mu$ L) was carefully added to the subarray and was allowed to incubate for 1h in the dark, followed by the washing procedure. Then, the subarrays were incubated with 100  $\mu$ L pre-mixed solution above for 1 h in the dark. After incubation, the slide was performed using a washing procedure and kept in the dark before analysis.

Screened arrays were dried by centrifugation and immediately scanned for fluorescence on a GenePix 4000 B microarray scanner (Molecular Devices). The detection gain was adjusted to avoid saturation of the signal. The data were processed with GenePix Pro 7 software and further analyzed using Microsoft Excel macro. The mean fluorescent intensities (corrected for mean background) and standard deviations (SD) were calculated (n = 4). Data were fitted using Prism software Version 8.3.0 (GraphPad Software, Inc). Bar graphs represent the mean  $\pm$  SD for each compound.

## 4.4 MIRAGE compliant Glycan Microarray Document

Supplementary Glycan Microarray Document according to MIRAGE Guidelines (doi:10.3762/mirage.3)

	Description
1. Sample: Glycan Binding	g Sample
Description of Sample	The human Siglecs, Plant lectins used in this work are described in SI section <u>2. Materials</u> and methods
Sample modifications	Not relevant.
Assay protocol	The incubation protocol was included in SI section <u>4.3 Screening of proteins</u> .
2. Glycan Library	
Glycan description for defined glycans	66 synthetic glycans are listed in Fig. 1.
Glycan description for undefined glycans	Not relevant.
Glycan modifications	The synthesis of glycans was described in SI section <u>3. Experimental procedures.</u>
3. Printing Surface; e.g., N	ficroarray Slide
Description of surface	Covalent arrays were prepared in this work. The details are included in SI section $4.2$ Glycan microarray printing.
Manufacturer	The details are included in SI section <u>4.2 Glycan microarray printing.</u>
Custom preparation of surface	Not relevant.
covalent Immobilization	The details are included in SI section <u>4.2 Glycan microarray printing</u> .
4. Arrayer (Printer)	
Description of Arrayer	The details are included in SI section <u>4.2 Glycan microarray printing</u> .
Dispensing mechanism	Non-contact liquid delivery with PDC nozzle.
Glycan deposition	The details are included in SI section <u>4.2 Glycan microarray printing</u> .

Printing conditions The details are included in SI section <u>4.2 Glycan microarray printing</u> .					
5. Glycan Microarray with	"Map"				
Array layout	The array layout of array was described in SI section <u>4.2 Glycan microarray printing</u> .				
Glycan identification and quality control	The structure of glycans was confirmed via NMR and HRMS as described in SI section <u>3</u> . <u>Experimental procedures</u> . The quality control of the arrayed glycans was performed using plant lectins as shown in SI section <u>Fig. S6</u> .				
6. Detector and Data Processing					
Scanning hardware	GenePix 4000B (Molecular Devices, Berkshire, UK)				
Scanner settings	The details are included in SI section <u>4.3 Screening of proteins.</u>				
Image analysis software	The details are included in SI section <u>4.3 Screening of proteins.</u>				
Data processing	The details are included in SI section <u>4.3 Screening of proteins.</u>				
7. Glycan Microarray Data	a Presentation				
Data presentation	Siglecs binding results are presented as heat map (Fig. 8) in the main text and corresponding histogram charts in SI section (Fig. S5). Plant lectins binding results are displayed in SI section by the histogram charts and heat map (Fig. S6).				
8. Interpretation and Conc	lusion from Microarray Data				
Data interpretation	No software or algorithms were used to interpret processed data.				
Conclusions	Different glycan has different preferences for different proteins.				

## 5. References

- 1. Zheng, Y.; Zhang, J.; Meisner, J., et al., Cofactor-Driven Cascade Reactions Enable the Efficient Preparation of Sugar Nucleotides. *Angew Chem Int Ed Engl* **2022**, *61* (20), e202115696.
- 2. Wei, F.; Yuan, R.; Wen, Q., et al., Systematic Enzymatic Synthesis of dTDP-Activated Sugar Nucleotides. *Angew Chem Int Ed Engl* **2023**, *62* (20), e202217894.
- 3. Wang, S.; Zhang, J.; Wei, F., et al., Facile Synthesis of Sugar Nucleotides from Common Sugars by the Cascade Conversion Strategy. *J Am Chem Soc* **2022**, *144* (22), 9980-9989.
- 4. Rodrigues, E.; Jung, J.; Park, H., et al., A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. *Nat Commun* **2020**, *11* (1), 5091.
- 5. Li, Y. H.; Yu, H.; Cao, H. Z., et al., Pasteurella multocida CMP-sialic acid synthetase and mutants of Neisseria meningitidis CMP-sialic acid synthetase with improved substrate promiscuity. *Appl Microbiol Biot* **2012**, *93* (6), 2411-2423.
- Yu, H.; Huang, S.; Chokhawala, H., et al., Highly Efficient Chemoenzymatic Synthesis of Naturally Occurring and Non-Natural α-2,6-Linked Sialosides: A P. damsela α-2,6-Sialyltransferase with Extremely Flexible Donor– Substrate Specificity. *Angew Chem Int Ed Engl* 2006, 45 (24), 3938-3944.
- 7 Xu, Y.; Fan, Y.; Ye, J., et al., Successfully Engineering a Bacterial Sialyltransferase for Regioselective α2,6sialylation. *ACS Catal* **2018**, *8* (8), 7222-7227.
- 8. Talafová, K.; Hrabárová, E.; Nahálka, J., A semi-multifunctional sialyltransferase from Bibersteinia trehalosi and its comparison to the Pasteurella multocida ST1 mutants. *J Biotechnol* **2015**, *216*, 116-124.
- 9. Mertsch, A.; He, N.; Yi, D., et al., An alpha2,3-Sialyltransferase from Photobacterium phosphoreum with Broad Substrate Scope: Controlling Hydrolytic Activity by Directed Evolution. *Chemistry* **2020**, *26* (50), 11614-11624.
- 10. Schwardt, O.; Visekruna, T.; Zenhäusern, G., et al., Cloning, Expression, and Preparative Application of a Mutated, Bifunctional  $\alpha(2\rightarrow 3/8)$ -Sialyltransferase from Campylobacter jejuni. *J Carbohydr Chem* **2007**, *25* (7), 543-556.
- 11. Xu, G.; Kiefel, M. J.; Wilson, J. C., et al., Three Streptococcus pneumoniae sialidases: three different products. *J* Am Chem Soc 2011, 133 (6), 1718-21.
- 12. Rasko, D. A.; Wang, G.; Palcic, M. M., et al., Cloning and Characterization of the α(1,3/4) Fucosyltransferase of Helicobacter pylori. *J Biol Chem* **2000**, *275* (7), 4988-4994.
- 13. Luo, Y. W.; Wang, Y. Q.; Tian, Y. P., et al., "Two Birds One Stone" Strategy for the Site-Specific Analysis of Core Fucosylation and GlcNAcylation. *J Am Chem Soc* **2023**, *145* (29), 15879-15887.
- 14. Tian, Y. P.; Wang, Y. Q.; Yin, H. B., et al., A Sensitive and Reversible Labeling Strategy Enables Global Mapping of the Core-Fucosylated Glycoproteome on Cell Surfaces. *Angew Chem Int Ed Engl* **2022**, *61* (49).
- 15. Wei, F.; Zang, L.; Zhang, P.; Zhang, J.; Wen, L., Concise chemoenzymatic synthesis of N-glycans. *Chem* **2024**. doi.org/10.1016/j.chempr.2024.05.006.
- Wen, L. Q.; Zheng, Y.; Jiang, K., et al., Two-Step Chemoenzymatic Detection of Acetylneuraminic Acid-α(2-3)-Galactose Glycans. J Am Chem Soc 2016, 138 (36), 11473-11476.
- 17. Ye, J. F.; Xia, H.; Sun, N., et al., Reprogramming the enzymatic assembly line for site-specific fucosylation. *Nat Catal* **2019**, *2* (6), 514-522.
- 18. Yu, H.; Chokhawala, H.; Karpel, R., et al., A multifunctional sialyltransferase:: A powerful tool for the synthesis of sialoside libraries. *J Am Chem Soc* **2005**, *127* (50), 17618-17619.
- 19. Yu, H.; Thon, V.; Lau, K., et al., Highly efficient chemoenzymatic synthesis of beta1-3-linked galactosides. *Chem Commun* **2010**, *46* (40), 7507-9.



# 6. NMR spectra
























































































S108










































220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)





















S137




















































Contraction of the second s 10 10 10 10 10 10 1.1 Π AULT AN AUTOM n 50 210 do 10 100 da 40 10 200 110 30 150 140 120 100 (pp



S159










































































































S205























230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)






S219











